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1 ZUSAMMENFASSUNG 
Gefässwandzellen, auch bekannt als Endothelzellen, kleiden die innere Wand aller 
Lymph- und Blutgefässe aus und bilden dabei eine äusserst kompakte Einzelzell-
schicht (auch Monolayer genannt). In gesunden Erwachsenen teilen sich nur gerade 
0.01 % der Endothelzellen, während sich die anderen 99.99 % in einer Ruhephase 
(auch Quiescence genannt) befinden. Dabei sind die Zellen äusserst resistent, so-
wohl gegen den programmierten Zelltod (Apoptose) wie auch gegen Einflüsse 
wachstumsfördernder Faktoren [1]. Dieser physiologische Zustand der Endothelzel-
len ist von zentraler Bedeutung für die gesamte Blutversorgung und muss ständig 
vom Körper überwacht und aufrechterhalten werden [2, 3]. Störungen dieser en-
dothelialen Barriere stehen dann auch in Verbindung mit verschiedenen Krankheiten 
wie Arteriosklerose und Krebs [4].  
Man nimmt an, dass Zell-Zellkontakt-Moleküle das Wachstum inhibieren wenn die 
Zellen dicht sind und sich berühren. Wahrscheinlich werden dadurch Signalkaskaden 
reguliert, wie zum Beispiel die Rezeptor-Tyrosinkinasen (RTK) [5].  
Die Sprouty (SPRY) Proteine sind wichtige Hemmproteine von RTK-induzierten Sig-
nalkaskaden, die unter anderem die MAPKinase ERK1/2 aktivieren. Das in Blutge-
fässen stark exprimierte SPRY2 Protein reguliert MAPK Signalkaskaden in der emb-
ryonalen Entwicklung [6, 7], in der Organ Bildung [8] und auch während der Angio-
genese [9]. In Endothelzellen wird SPRY2 durch FGF2 induziert und wirkt danach als 
Feedbackinhibitor von derselben Signalkaskade [10]. Es ist aber unbekannt, ob 
SPRY2 und seine Funktion in die Zellkontakt-Inhibition involviert sind. 
In dieser Doktorarbeit untersuchen wir daher den potentiellen Einfluss von SPRY2 
auf die Bildung eines funktionellen Monolayers, welcher aus primären Mäuseaorta 
Endothelzellen (MAECs) besteht. Insbesondere haben wir uns für den Mechanismus 
interessiert, der es den Endothelzellen erlaubt, eine erhöhte Dichte an Zellen wahr-
zunehmen und darauf adäquat zu reagieren. Das heisst, die Zellen stoppen die 
Proliferation/Migration und bilden stattdessen einen kompakten Monolayer. 
Mit einer Serie von Experimenten versuchten wir herauszufinden, ob die Expression 
vom SPRY2 von der Zelldichte beeinflusst wird. Dafür wurden MAECs zuerst dünn 
ausgesät und so lange kultiviert, bis sie schliesslich nach vier Tagen einen dichten 
Monolayer gebildet hatten. Nach einem Tag zeigten die Zellen eine dünn besiedelte 
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Kultur, die kaum SPRY2 Proteine produzierte. Nach 48 Stunden wiesen die Zellen 
eine erhöhte Zelldichte auf und exprimierten eine beachtliche Menge an SPRY2. 
Schliesslich, nach 72 bis 96 Stunden, waren die Zellen grösstenteils dicht und stell-
ten grosse Mengen an SPRY2 her. Diese stark erhöhte SPRY2 Proteinmenge korre-
lierte mit reduzierter ERK1/2 Phosphorylierung.  
Insbesondere nach 48 Stunden war der Anstieg von SPRY2 von einer erhöhten Ex-
pression des Hypoxie-Induzierbaren Faktors 1α (HIF-1α) begleitet. Eine Echtzeit-
messung des Sauerstoffgehalts bestätigte, dass die Kultur von dicht wachsenden 
Zellen einen erhöhten Sauerstoffverbrauch vorwies, der nach 48 Stunden sein Maxi-
mum erreichte. Weitere Experimente zeigten dann, dass SPRY2 Protein (nicht die 
Spry2 mRNA) durch künstlich herbeigeführte Hypoxie erhöht werden konnte. Wurden 
dichte Endothelzellen in einer Hungerlösung (Medium ohne Kälberserum) kultiviert, 
senkte sich der Sauerstoffverbrauch der Kultur wodurch die Hypoxie verschwand. 
Interessanterweise blieben die Mengen an SPRY2 Protein auch in einer dichten und 
normoxischen Kultur stark erhöht (75-mal mehr SPRY2 Protein als in einer dünnen 
Kultur). Diese Resultate wiesen auf einen zusätzlichen, Hypoxie-unabhängigen Me-
chanismus hin, der für die Stabilisierung von SPRY2 in dichten Zellkulturen mitver-
antwortlich sein muss, nämlich Zell-Zellkontakte. Tatsächlich, wenn die Kalzium ab-
hängige Zell-Zellkontakte durch EGTA aufgebrochen wurden, verschwand die 
SPRY2 Proteine (nicht die Spry2 mRNA) innerhalb von 30 Minuten. Umgekehrt, beim 
Austausch der EGTA Lösung durch normales Medium, bildeten sich neue Zell-
Zellkontakte und SPRY2 konnte wieder nachgewiesen werden. 
In einem nächsten Schritt verglichen wir die Fähigkeit von SPRY2-exprimierenden 
MAECs (Spry2fl/fl) mit solchen die kein SPRY2 Protein vorwiesen (Spry2-/-). Wir konn-
ten zeigen, dass in Anwesenheit des Wachstumsfaktors FGF2, die Spry-/- MAECs 
keinen funktionellen Monolayer bilden können. Diese Zellen wiesen eine erhöhte 
ERK1/2 Aktivität auf, teilten sich unkontrolliert und nahmen eine spindelähnliche 
Form an. Die normale Morphologie des Monolayers konnte schliesslich durch eine 
Inhibierung der ERK1/2 Aktivität wiederhergestellt werden. 
Mit dieser Dissertation zeigen wir einen neuartigen Mechanismus, durch welchen die 
monozelluläre Endothelschicht in Blutgefässen stabil wird und bleibt. Dabei wird das 
SPRY2 Protein benötigt, um die Zellteilung zu stoppen wenn die Endothelzellen hohe 
Dichten erreichen. Durch die Inhibierung der FGF2-ERK1/2 Signalkaskade trägt 
SPRY2 dazu bei die endotheliale Barriere zu bilden und aufrechtzuerhalten. 
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2 SUMMARY 
Arranged in a tight monolayer, endothelial cells line the inner wall of all blood and 
lymphatic vessels. In the healthy adult, only 0.01% of the endothelial cells are divid-
ing. The other 99.99 % endothelial cells show a physiological state, where they resist 
apoptosis and remain quiescent even in the presence of angiogenic factors [1]. This 
highly functional endothelial monolayer allows mature blood vessels to control vessel 
wall permeability and supply the organs with oxygen and nutrients [2, 3]. However, 
this physiological state (defined as vascular integrity) needs to be actively maintained 
[3]. Disturbed integrity of the endothelial monolayer contributes to the pathogenesis 
of several diseases including atherosclerosis and cancer [4].  
Several surface molecules associated with adherens and tight junctions have been 
implicated in mediating cell-contact inhibition (cells undergo growth arrest when they 
come into contact with each other) and vascular integrity through the regulation of 
intracellular signaling cascades such as receptor tyrosine kinase (RTK) signaling [5].  
The Sprouty (SPRY) family of proteins is an important class of negative regulators of 
RTK dependent MAPK activation. Sprouty2 (SPRY2), the SPRY family member with 
high expression in endothelial cells [9], modulates MAPK-signaling in embryogenesis 
[6, 7], organ development [8], and angiogenesis [9]. In endothelial cells, SPRY2 is 
induced by FGF2 and inhibits FGF2-stimulated growth and sprouting by inhibiting the 
MAPK extracellular signal-regulated kinase 1/2 (ERK1/2) [10]. However, it remains 
unknown whether contact inhibition involves SPRY2 function.  
In this thesis, we have therefore examined the potential role of Sprouty2 (SPRY2) in 
the formation maintenance of a functional, quiescent monolayer in mouse aortic en-
dothelial cells (MAECs) in vitro. We were particularly interested of how endothelial 
cells process signals arising from increasing cell density to allow a switch from a pro-
liferative, migratory phenotype to a quiescent, impermeable monolayer. 
To investigate whether cell density affects SPRY2 expression, we have monitored 
the protein expression levels of SPRY2 in MAECs growing from an initially sparse 
culture to a confluent monolayer over a time period of four days. Nearly absent in 
sparse cells (24 hours after plating), SPRY2 protein expression markedly increased 
when cells were sub-confluent (after 48 hours) and peaked when cells showed con-
fluence (72 to 96 hours after plating). Cell density induced SPRY2 also correlated 
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with decreased FGF2-induced ERK1/2 phosphorylation. The increase in SPRY2 pro-
tein expression was accompanied by elevated hypoxia-inducible factor 1α (Hif-1α) 
expression when cells were growing to confluency. Real-time measurement of oxy-
gen levels in MAECs confirmed that the O2 consumption peaked after 48 hours creat-
ing local hypoxia in the endothelial layer. SPRY2 protein but not mRNA levels in-
creased when cells were grown in hypoxia (1% O2). Thus, hypoxia drives SPRY2 
protein induction on a posttranscriptional level. 
However, when serum starvation of the MAECs restored normal oxygen levels, 
SPRY2 expression remained at high levels (~75 fold induction) in confluent com-
pared to sparsely plated cells. These observations pointed to an additional mecha-
nism which stabilized SPRY2 protein expression at high cell densities: intact cell-cell 
contacts. Indeed, SPRY2 protein but not mRNA expression vanished when Ca2+-
dependent cell-cell contacts were disrupted by ethylene glycol tetraacetic acid (EG-
TA). Conversely, removing EGTA restored cell-cell contacts and SPRY2 protein ex-
pression. 
Finally, we demonstrate that dense SPRY2-/- MAECs were incapable of forming a 
functional endothelial monolayer in the presence of FGF2: SPRY2-/- MAECs exhibit-
ed spindle-like shapes and generated a highly permeable cell layer with a ~4 fold 
increase in permeability compared to wild type cells. In addition, dense SPRY2-/- 
MAECs exhibited a twofold increase in ERK1/2 activity, did not become quiescent 
and continued to proliferate at confluence. As a consequence, when inhibiting 
ERK1/2 activity by UO126, SPRY2-/- cells regained the capacity of forming a wild type 
cobblestone shaped endothelial monolayer.  
Thus, with this PhD thesis we show a novel mechanism how vessels achieve and 
maintain vascular stabilization , specifically that cell density-induced SPRY2 is re-
quired to establish endothelial quiescence and barrier integrity through the inhibition 
of FGF2-ERK1/2 signaling. 
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3 INTRODUCTION 
3.1 Vascularization of the embryo 
In early embryonal development, oxygenation of a cell aggregate can be maintained 
by diffusion of molecular oxygen (O2) [11]. At a critical tissue size a vascular system 
has to be created to keep up O2 supply for each cell and forming tissue. Therefore 
the growth of the vascular tree tightly accompanies embryonic development. The 
newly formed vessels provide oxygen, nutrients and growth factors and thereby pro-
mote growth and morphogenic maturation of the developing organs [11].  
Vasculogenesis, the formation of new blood vessels when there are no pre-existing 
ones, initiates embryonic vascular growth. During vasculogenesis endothelial progen-
itors (angioblasts) are recruited from various embryonic regions. These angioblasts 
proliferate, migrate and differentiate into endothelial cells, which eventually give rise 
to a primitive vascular network composed of small capillaries [12, 13].  
 
 
 
Figure 1. Vascular development in the embryo. Development of the vascular systems: during vas-
culogenesis, endothelial progenitors give rise to a primitive vascular labyrinth of arteries and veins; 
during subsequent angiogenesis, the network expands, pericytes (PCs) and smooth muscle cells 
(SMCs) cover nascent endothelial channels, and a stereotypically organized vascular network emerg-
es. Lymph vessels develop via trans-differentiation from veins [11, 14]. 
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Distinct signals specify arterial or venous differentiation [15]. Angiogenesis, the 
sprouting of preexisting vessels, ensures expansion of the vascular network [16-18]. 
Attracted mesenchymal stem cells and neurocrest cells differentiate into vascular 
smooth muscle cells (VSMCs) and pericytes (VSMCs like cells) and stabilize the de-
veloping vessels [14] (Fig. 1). 
 
3.2 Angiogenesis in adults 
In the adult, most vessels remain quiescent and only 0.01 % of the endothelial cells 
are dividing. Angiogenesis occurs regularly only during wound healing, in the buildup 
of the endometrium during the ovarian cycle and in the placenta during pregnancy 
[11]. However, ECs keep their ability to divide rapidly in response to a physiological 
stimulus and are able to revascularize the damaged tissue after an injury. Angiogen-
esis begins when a quiescent microvessel is activated by angiogenic stimului, such 
as VEGF, Ang-2, FGFs or hypoxia [11]. The activated vessel eventually dilates, en-
dothelial cells loosen their junctions and pericytes detach from the vessel wall. Matrix 
metalloproteinases (MMPs) degrade the basement membrane allowing ECs to mi-
grate in response to chemotactic signal. VEGF increases the permeability of the en-
dothelial cell layer and allows the plasma proteins to extravasate form the vessel. 
The resulting provisional extracellular matrix provides a scaffold for the endothelial 
migration columns [16]. A concentration gradient of VEGF selects a tip cell which 
then leads the way of the migrating column. To prevent endothelial cells from moving 
en masse towards the angiogenic stimulus, the tip cell immediately inhibits tip cell 
phenotype of its neighboring cells predominantly via DLL4-Notch signaling converting 
them to stalk cells. The main task of the stalk cells is to elongate the sprout by prolif-
eration and to finally form a lumen [16]. A basement membrane forms and pericytes 
as well as smooth muscle cells attach to newly formed vessel. Blood-vessel sprouts 
will then fuse with other sprouts to build on new circulatory systems. In contrast to tip 
and stalk cells, phalanx cells increase quiescence in the presence of VEGF [19]. 
They express a soluble form of the VEGF receptor 1 (sFLT1). sFLT1 acts as a VEGF 
trap to counteract the tip cell-inducing activity of VEGF, thereby preventing the for-
mation of excessive branches [20, 21] (Fig. 2).  
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Figure 2. Schematic representation of the angiogenic process. Angiogenesis starts from pre-
existing vessels with the conversion of a previously quiescent EC into a tip cell. The tip cell forms filo-
podia to probe the surrounding environment and to migrate towards the angiogenic stimulus. Stalk 
cells proliferate to prolong the column, merge and form vacuoles to give rise to the vascular lumen. 
The newly formed vessel finally undergoes stabilization and maturation via intercellular adhesion and 
mural cell coverage. The phalanx cells remain quiescent and prevent the formation of supernumerary 
branches (adapted from [22]).  
 
3.3 Maturation and stabilization of newly formed blood vessels 
Vessel maturation – the stepwise transition from an actively growing vascular bed to 
a quiescent, mature network – involves suppression of endothelial proliferation, mi-
gration and sprouting, and stabilization of the nascent vascular tubes via incorpora-
tion of mural cells into the vessel wall [23, 24].  
Sprouting endothelial cells release platelet-derived growth factor-B (PDGFB) that at-
tract co-migrating pericytes (smooth muscle-like cells), which in turn express 
PDGFBR. Pericytes establish direct cell–cell contact with ECs to cover capillaries 
and immature blood vessels and regulate morphology and function of the vessels 
[25, 26]. Endothelial cells (ECs) release transforming growth factor-β1 (TGFβ1) to 
promote the differentiation of progenitor cells into VSMCs [40, 41]. VSMCs form lay-
ers around mature and larger diameter vessels, such as arteries and veins, and are 
separated from the endothelium by a basement-membrane layer [14, 27]. 
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Figure 3. Wall composition of nascent versus mature vessels. (a) Nascent vessels consist of a 
tube of ECs. These mature into the specialized structures of capillaries, arteries and veins. (b) Capil-
laries consist of ECs surrounded by basement membrane and a sparse layer of pericytes embedded 
within the EC basement membrane. (c) Arterioles and venules have an increased coverage of mural 
cells compared with capillaries. Pre-capillary arterioles are completely invested with vascular SMCs 
that form their own basement membrane and are closely packed and tightly associated with the endo-
thelium. (d) The walls of larger vessels consist of three specialized layers: an intima composed of 
endothelial cells, a media of VSMCs and an adventitia of fibroblasts, together with matrix and elastic 
laminae. VSMCs and elastic laminae contribute to the vessel tone and mediate the control of vessel 
diameter and blood flow [23].  
 
3.4 Arteriogenesis – vessels adapt to their requirements  
The complexity of our cardiovascular system calls for a variety of different vessels. 
Starting from the capillaries that reach every single cell and are so tiny, only one 
blood cell can move through them at a time, and ending up with the aorta which al-
lows the heart to pump 5-6 liters of blood every minute into the systemic circuit [1]. 
The cardiovascular system is composed of the heart and circulatory system which 
can be divided into the pulmonary circuit and the systemic circuit. In the pulmonary 
circuit, the right ventricle pumps oxygen-poor blood through the pulmonary artery to 
the lungs. The pulmonary vein returns the oxygen-rich blood to the left ventricle. The 
large, highly pressurized system is responsible for the systemic distribution. It starts 
with the left ventricle, pumping oxygenated blood through the aorta, large arteries, 
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small arteries, arterioles, and the capillary system where the gas and metabolic ex-
changes take place, then venules, small veins, and large veins ending with the right 
heart completing the circulatory system [1].  
Arteriogenesis describes the remodeling adaption of pre-existing vessels to the cor-
responding requirements. Physical forces such as blood flow, blood pressure and 
shear stress stimulate arteries to increase their luminal diameter. Smooth muscle 
cells proliferate and surround the vessels in several layers to increase their stability 
necessary to withstand the blood pressure [28, 29].  
Venules have irregularly arranged pericytes and are composed of thinner EC walls 
with valves to prevent backflow of blood. Capillaries are the most abundant vessels in 
our body and are covered by a sparse layer of pericytes. Because of their wall struc-
ture and large surface-area-to-volume ratio, these vessels form the main site of ex-
change of nutrients between blood and tissue [23]. Depending upon the organ or tis-
sue, the capillary endothelial layer is continuous (as in muscle), fenestrated (as in 
kidney or endocrine glands) or discontinuous (as in liver sinusoids). The endothelium 
of the blood-brain barrier or and the blood-retina barrier are further specialized to in-
clude high numbers of tight junctions, and are thus virtually impermeable to various 
molecules [1, 23]. 
 
3.5 The hypoxic response via HIF-1α 
Oxygen-sensing mechanisms help mammals to quickly adapt to hypoxia, by increas-
ing respiration, blood flow, erythrocyte count and angiogenesis [30]. During normoxic 
conditions, prolyl hydroxylases (PHDs) hydroxylate specific proline residues in HIF 
target proteins, marking them for recognition by the von Hippel-Lindau (VHL) E3 
ubiquitin ligase complex, which subsequently leads to proteasomal degradation of 
the HIF-1α subunit. Three prolyl hydroxylases (PHD1, PHD2 and PHD3) have been 
identified, but PHD2 predominantly regulates basal HIF-1α levels under normoxic 
conditions [31].  
Under aerobic conditions the dioxygenases utilize O2 as substrate. One oxygen atom 
is inserted into the HIF-1α prolyl residue to form 4-hydroxyl group and the other oxy-
gen atom is inserted into the co-substrate α-ketoglutarate, forming succinate and 
CO2 as side products [31]. Low O2 levels inactivate PHD and therefore stabilize HIFs 
[32]. The stabilized HIF-1α subunits form heterodimers with the constitutively ex-
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pressed and oxygen independent HIF-1β subunit. The heterodimeric transcription 
factor activates the expression of many angiogenic genes and thereby initiates angi-
ogenesis (Fig. 4). 
Under normoxic conditions, HIF proactively increases in response to growth stimuli, 
since enhanced proliferation eventually leads to higher oxygen consumption [33]. 
The growing cell thus profits from an anticipatory increases in HIF-dependent target 
gene expression. 
 
 
 
Figure 4. Molecular mechanisms of HIF-1α regulation. In normoxia, the cellular oxygen sensors 
(PHDs) hydroxylate specific proline residues (Pro402 and Pro564) of HIF-1α, leading to its pro-
teasomal degradation mediated by pVHL, an E3 ubiquitin ligase. During hypoxia, HIF-1α is not ubiqui-
tinylated or degraded, and acts as a transcription factor that binds to HREs to induce expression of a 
plethora of target genes, including VEGF, which promotes angiogenesis, and genes involved in an-
aerobic metabolism [34]. 
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3.6 Physiological, pathological and therapeutic angiogenesis  
Physiological angiogenesis is temporally limited, and exclusively occurs when need-
ed. By contrast, tumors angiogenesis can persist for years and is morphologically 
and functionally abnormal. The tumor vasculature for example is characterized by 
dilated and elongated vessel shapes, leaky sprouts, and decreased vessel density. 
This abnormal vessel architecture is due to the continuous and excessive release of 
growth factors in solid tumors [11]. In age-related macular degeneration, abnormal 
growth of leaky blood vessel causes loss of vision due to bleeding which irreversibly 
damages photoreceptors. In atherosclerosis, uncontrolled neovascularization in 
plaques promotes growth and destabilizes plaque structure [35]. Several drugs have 
been designed that counteract excessive pathological angiogenesis: the most fa-
mous drugs Avastin® and Lucentis® target the VEGF system and are successfully 
used to treat cancer and certain retinopathies such as age-related macular degen-
eration [36]. Insufficient vessel growth and abnormal vessel regression on the other 
hand not only cause heart and brain ischemia, but can also lead to neurodegenera-
tion, hypertension, respiratory distress, osteoporosis and other disorders. Pro-
angiogenic molecules such VEGF and FGF are still considered as potential drugs to 
treat ischemia with therapeutic angiogenesis [37, 38], in spite of disappointing early 
clinical trials results.  
 
3.7 In-vitro angiogenesis 
Studying angiogenesis in-vitro reduces the number of animals used for in-vivo exper-
iments. Capillary-like sprouts emerging in these cultures represent early to midterm 
steps of angiogenesis and can be quantified to study potential angiogenic com-
pounds and underlying mechanisms [39]. Nicosia et al. embedded rat aortic rings in 
fibrin or collagen gels supplemented with an optimized endothelial growth medium. 
The endothelial cells generated branching microvessels in the absence of serum or 
other soluble protein supplements. The angiogenic response was quantitated by 
counting the newly formed microvessels in the living cultures [40]. Also little squares 
of thoracic aortas can be placed onto the gels endothelium facing down and covered 
with collagen or fibrinogen [41]. Furthermore, small pieces of left ventricular myocar-
dium can be cultured in three-dimensional fibrin gels and emerging endothelial 
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sprouts studied by morphometry [42] (Fig. 5A). Instead of tissue pieces, endothelial 
cell spheroids embedded in collagen matrix can also be used to investigate emerging 
capillary-like structures [43-45] (Fig. 5B).  
 
 
 
Figure 5. In vitro angiogenesis. (A) Three-dimensional in vitro angiogenesis assay using heart or 
aortic tissue in fibrin gels. Capillary tubes bifurcate and give rise to a primitive capillary tube network. 
(A, lower panel) (adapted from [39]). (B) Sprouting angiogenesis. Spheroids of ca. 400 endothelial 
cells were mixed with collagen and stimulated with growth factors to obtain outgrowth of endothelial 
sprouts. (C1,C2) Endothelial cells in culture display both the ‘activated’ and ‘quiescent’ endothelial 
phenotype [2]. The behaviour of growing ‘angiogenic’ cells compares to that of an in vitro sparse cul-
ture (C1), whereas a tight monolayer of cultured endothelial cells arranged in a cobblestone morphol-
ogy demonstrates quiescence (C2). 
 
3.8 The Endothelial monolayer 
The endothelium is a monolayer of cells that form a continuous layer on the intimal 
surface of the entire cardiovascular system, including the arteries, veins, and cham-
bers of the heart (endocardium) [46].  
Interendothelial junction structures maintain the integrity [2] of the endothelium but 
also allow the endothelial layer to act as a selective barrier controlling permeability 
and transport of solutes and macromolecules across the vascular wall [47]. Beside its 
barrier function, the endothelium helps to control the maintenance of a non-
thrombogenic surface, leukocyte adhesion, and angiogenesis. Furthermore, the en-
dothelial cells control the proliferation and the contraction of the underlying vascular 
smooth muscle cells by producing nitric oxide and other regulatory factors, thereby 
contributing to the local regulation of the vasomotor tone [48].  
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The observation that endothelial cells line the inner wall of all blood and lymph ves-
sels as a tight monolayer led to the view that endothelial monolayers can be studied 
in-vitro in two-dimensional systems. When plated at sparse conditions, endothelial 
cells behave like growing ‘angiogenic’ cells when stimulated with growth factors (Fig. 
5C1). Plated at confluence, endothelial cells form a tight monolayer arranged in a 
cobblestone like morphology comparable to quiescent endothelial cells in a mature 
vessel [2] (Fig. 5C2).  
Endothelial cultures are used to study many different vascular functions such as vas-
cular integrity and permeability [49-51], responses to all kinds of physiological stimuli, 
functions related to vessel remodeling and angiogenesis, and interactions with other 
cells such as smooth muscle cells, pericytes, leukocytes and tumor cells (summa-
rized in [52]).  
 
 
 
 
Figure 6. Top view of a confluent endothelial monolayer. The figure shows a confluent monolayer 
composed of primary mouse aortic endothelial cells. At this stage, the endothelial cells display a qui-
escent phenotype (defined as reversible cell growth / proliferation arrest). 
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3.8.1 Endothelial cell-cell contacts 
As a gatekeeper the endothelium controls the penetration of blood proteins and cells 
through the vessel wall [2]. Cell-cell adhesive structures such as adherens and tight 
junctions maintain endothelial integrity, and at the same time, allow a dynamic regu-
lation of leukocyte transmigration during the inflammatory response and cellular re-
modeling during angiogenesis [53]. 
In endothelial cells three types of intercellular junctions, namely adherens, tight, and 
gap junctions contribute to the structural integrity of the endothelium. Tight and ad-
herens junctions establish and maintain cell-to-cell adhesion, gap junctions control 
the passage of water, ions, and other small molecules from one cell to another. All 
three junctions are formed by distinct transmembrane proteins that undergo homo-
philic cell-cell interactions and promote the transfer of intracellular signals [54]. 
 
3.8.2 Endothelial adherens junctions 
Adherens junctions are protein complexes that occur at cell–cell junctions in epithelial 
and endothelial tissues. Cadherins are the central part of endothelial adherens junc-
tions and form zipper-like structures along intercellular contacts. Beside promoting 
cell-cell adhesion, cadherins transfer various signals and are implicated in mediating 
contact inhibition [55].  
In endothelial cells, adherens junctions consist of the calcium dependent N-cadherin 
and the endothelial specific VE-cadherins (cadherin-5) which localizes at sites of cel-
lular contacts [56], connecting the site of the junction to the actin cytoskeleton. VE-
cadherins connect adjacent cells by forming hexamers [57, 58]. VE-cadherins form 
trimers in cis at the cell surface and interact in trans with a trimer of a neighboring 
cell. This adhesive interaction of two cadherin trimers strictly depends on extracellular 
calcium [59]. VE-cadherin binds β-catenin, plakoglobin, and p120 through its cyto-
plasmic tail. β-Catenin and plakoglobin in turn link to α-catenin, which binds vinculin, 
α-actin, and zonula occludens protein 1 (ZO-1). These interactions mediate the an-
chorage to actin microfilaments [54]. VE-cadherin also regulates vascular permeabil-
ity and leukocyte transmigration besides maintaining integrity of the endothelium [60]. 
VEGF induces tyrosine phosphorylation of VE-cadherin, β-Catenin and plakoglobin 
thereby decreasing the association of VE-cadherin with the cytoskeleton [61, 62].  
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3.8.3 Endothelial tight junctions 
Tight junctions (TJ) localizes to the zonula occludens, the area where the mem-
branes of adjacent cells meet and form an almost impermeable endothelial monolay-
er. Tight junctions are distributed heterogeneously across the vascular tree and show 
variations in number and composition. Endothelial cells of the large arteries and the 
blood brain barrier (BBB) show a well-developed TJ-system whereas capillaries ECs 
contain few and rudimentary organized TJs [47].  
Claudins form the major adhesive components of tight junctions. Beside claudin-3 
and -11, endothelial cells specifically express Claudin-5 [63, 64]. Occludin, another 
transmembrane component requires the co-expression of junctional protein zona oc-
cludins-1 (ZO-1) for cell surface expression. The ZO proteins link claudins and oc-
cludins to the actin cytoskeleton [54]. Occludin is predominately expressed at cell-cell 
contacts in brain endothelial cells and only rarely in endothelial cells of non-neural 
tissue [65]. Accordingly, occludin downregulation associates with various disease 
states involving BBB or BRB disruption [47]. 
The junctional adhesion molecules A (JAM-A) colocalize with TJs and support cell-
cell adhesion via homophilic interactions [47, 66], mediate monocyte transmigration 
through the endothelial cell monolayer [67, 68], and participates in FGF2-induced 
angiogenesis [69]. As opposed to JAM-A, junctional localization of JAM-C increases 
paracellular permeability, possibly by modulating VE–cadherin cell–cell contacts [70]. 
At interendothelial junctions, JAM-C may also interact with JAM-B [71]. The JAM re-
lated transmembrane molecule ESAM [72] is implicate in tumor angiogenesis [73], 
and participates in neutrophil extravasation [74]. Nectins form another group of cell–
cell adhesion molecules [75, 76], associate with TJ and AJ proteins, and participate 
in the initial step of junction formation [47]. Endothelial cells express only nectin-2 (α-
herpes receptor) and Necl-5 (poliovirus receptor) [77, 78] (Fig. 7). 
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Figure 7. Schematic representation of tight and adherens junctions in endothelial cells. At tight 
junctions, adhesion is mediated by claudins, occludin, members of the junctional adhesion molecule 
(JAM) family and endothelial cell selective adhesion molecule (ESAM). At adherens junctions, adhe-
sion is mostly promoted by vascular endothelial cadherin (VE-cadherin), which, through its extracellu-
lar domain, is associated with vascular endothelial protein tyrosine phosphatase (VE-PTP). Nectin 
participates in the organization of both tight junctions and adherens junctions. Outside these junctional 
structures, platelet endothelial cell adhesion molecule (PECAM) contributes to endothelial cell–cell 
adhesion. In endothelial cells, neuronal cadherin (N-cadherin) is not concentrated at adherens junc-
tions, but instead probably induces the adhesion of endothelial cells to pericytes and smooth muscle 
cells [2, 4]. 
 
3.8.4 Contact inhibition and mitogenic quiescence 
The capacity for cells to regulate their proliferative responses in the context of cell-
cell contact is a fundamental requirement for the organization and maintenance of 
specialized tissues in multicellular organisms. Indeed, contact-mediated inhibition of 
growth is not restricted to cells in tissues but is a general property displayed by cul-
tured primary cells of many types, including endothelial, smooth muscle, epithelial, 
and other lineages [79]. Increasing cell-cell contacts in adherent cells eventually 
block the growth factor stimuli to proliferate in vitro. This density or contact-
dependent inhibition of cell proliferation (also known as cellular quiescence) is 
achieved at a specific saturation density [5, 80].  
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In endothelial cells, it is likely that the establishment of intercellular contacts transfers 
negative intracellular signals, which restrains the capacity of quiescent cells to re-
spond to proliferative signals such as VEGF, FGF and angiopoietin (ANG) [2]. In-
deed, contact inhibition is at least partially mediated by the establishment of cadher-
in-based junctions, since cell division is inhibited when cells are plated onto a sub-
strate containing VE-cadherin extracellular domains [81]. Accordingly, VE-cadherin-
deficient endothelial cells loose contact inhibition and display increased cell densities 
in response to VEGF stimulation. The VE-cadherin null cells show increased VEGF-
induced VEGFR-2 tyrosine phosphorylation, MAPK activity and enhanced cell prolif-
eration [82]. How endothelial cell keep quiescence in the presence of FGF is less 
understood. On the one hand, physiological FGF signaling is necessary for the 
maintenance of vascular integrity [83] and, on the other hand, FGF induces angio-
genesis [84]. Although cell confluence inhibits FGF induced p42/p44 MAPK (ERK1/2) 
activity in mouse vascular endothelial cells, it remains elusive whether VE-cadherins 
or other cell-cell contact molecules participate in this process [5]. Like the FGF-
system, the ANG1-Tie2 ligand-receptor system is in involved in vascular angiogene-
sis as well as in vascular stabilization [85]. In migrating endothelial cells, Ang1 induc-
es motility and Tie2 activation in cell-matrix contacts. In contrast, in contacting cells 
Ang1 induces Tie2 translocation to cell-cell contacts, promotes the formation of ma-
ture pericyte-covered vessels with tight cell-cell junctions [86], and further stabilizes 
the vasculature by enhancing Dll4/Notch signaling [87]. In contrast to Ang-1, Ang-2 
destabilizes the quiescent endothelium and primes it to respond to inflammatory (tu-
mor necrosis factor and interleukin-1) and angiogenic (VEGF) cytokines [88, 89]. 
 
3.8.5 Endothelial quiescence and the cytoskeleton 
Through their cytoplasmic tails, both adherens and tight junctions bind to cytoskeletal 
proteins that promote anchoring of junctions to actin microfilaments. Cytoskeletal as-
sociation is required for stabilization of the junctions, but also for the dynamic regula-
tion of junction opening and closing [90]. In endothelial cells, the process of actin 
polymerization is very dynamic, which allows for the rapid reorganization of actin 
structures and the transition from the quiescent phenotype, characterized by thick 
cortical actin ring and the absence of stress fibers, to the activated cell phenotype 
with thin or no cortical actin and abundant stress fibers [91]. Permeability-increasing 
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agonists such as LPS, thrombin and VEGF increase intracellular calcium levels and 
thereby activate the myosine light chain kinase MLCK allowing actin-myosin mediat-
ed EC contraction [92]. The contraction of the cytoskeleton and the loss of intercellu-
lar junctional organization lead to the appearance of paracellular gaps and eventually 
to the dysfunction of the endothelial barrier (Fig. 8). 
 
 
 
Figure 8. Cytoskeletal rearrangements in endothelial quiescence and barrier dysfunction. The-
se transmembrane complexes are linked to microfilaments, ensuring the cell cytoskeleton architectural 
integrity. In an agonist-challenged monolayer, the induction of stress fiber formation and the develop-
ment of acto-myosin-driven tension, together with the loss of intercellular junctional organization, lead 
to the appearance of paracellular gaps and the dysfunction of the endothelial barrier [91]. 
 
3.9 Altered vascular permeability and endothelial dysfunction 
Selective regulation of vascular permeability is achieved by regulation of the size and 
state of paracellular gaps and control of the transcellular transport. The normal vas-
culature demonstrates a certain level of basal permeability that varies among differ-
ent vascular beds [93]. Barrier hyperpermeability, necessary for example to provide 
the access of leukocytes to the pathogen is reversible and does not permanently dis-
turb vascular integrity. In this way the control of vascular permeability may be re-
stored once the triggering cause is removed [3, 93]. 
In extreme conditions, however, the integrity of the endothelial monolayer is severely 
affected and cell-to-cell junctions are disrupted. In pulmonary tissue, such vascular 
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leakage leads to subsequent liquid accumulation in the alveolar space and progres-
sive pulmonary failure [91].  
During ischemic stroke, emerging edema around the ischemic area extends brain 
damage [4]. Eventually, endothelial cells may detach from the vessel wall, creating 
areas of vascular damage and possibly small thrombi. In tumors, the vasculature is 
often fragile and exhibits altered permeability, leading to vessel leakage and hemor-
rhages [4]. High altitude cerebral edema (HACE) is a vasogenic edema characterized 
by the disruption of the blood–brain barrier by mechanical and biochemical factors. 
Cerebral capillary hypertension results from impairment of cerebral venous return 
during hypoxia-induced cerebral vasodilatation. HACE often occurs secondary to 
acute mountain sickness and or high altitude pulmonary edema due to thin air and 
resulting hypoxia. HACE causes disturbances of consciousness that may progress to 
deep coma, psychiatric changes of varying degree, confusion and ataxia of the way 
of walking. HACE may cause significant morbidity and occasionally death in other-
wise perfectly healthy people [94]. Alternatively, several chemical compounds includ-
ing bradykinin, histamine and VEGF [94-96] mediate BBB leakage and cerebral 
edema. 
Endothelial cells normally maintain vascular hemostasis and prevent thrombotic 
complications. However, when affected by infection, stress, hypertension, dyslipidem-
ia, or high homocysteine levels, endothelial cells undergo changes resulting in "endo-
thelial dysfunction," characterized by decreased endothelial expression of nitric ox-
ide, enhanced expression of proinflammatory adhesion molecules, and associated 
increased binding of circulating leukocytes to these cells [97]. Dysfunction is implicat-
ed as a key factor in the initiation and progression of inflammatory and atherogenic 
process that underlies coronary artery disease, peripheral ischemia, and stroke, and 
contributes to hypertension and heart failure [46, 98, 99]. 
 
3.9.1 The endothelial monolayer and Inflammation 
Inflammation is an important component of host defense against pathogens; howev-
er, excessive or uncontrolled inflammation can disrupt normal tissue homeostasis. 
Inflammatory processes are characterized by an increase in microvascular permea-
bility to macromolecules and immune cells [100]. Under normal conditions, circulating 
leukocytes adhere poorly to the endothelium. In response to inflammatory molecules 
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such TNF-α and IL-1 endothelial cells expresses adhesion molecules that bind cog-
nate ligands on leukocytes. Leukocytes then roll on the activated endothelial cells via 
selectin interactions and later firmly attach by integrin binding. Chemokines finally 
direct their diapedesis and migration into the intima where they fight the pathogens 
[101]. If the innate immune response has successfully removed the pathogen, the 
endothelial cells restore barrier function and normal tissue architecture. However, 
when the stimulus is not eliminated then inflammatory process will persist and acti-
vates the adaptive immune response. Persistent hyperpermeability leads to the ex-
cessive swelling of the tissue due to the fluid extravasation from vascular lumen. If 
the adaptive immune system fails to eradicate the antigen, the inflammatory process 
evolves to a more and more chronic form.  
 
3.9.2 Endothelial monolayer integrity in tumors 
A growing tumor may not exceed the size of 0.2-2 mm (the limit of oxygen and nutri-
ent diffusion) without acquiring an additional vasculature [102, 103]. When tumor 
cells get hypoxic they excessively produce VEGF, FGF and other growth factors to 
induce neovascularization of the hypoxic tumor area. Attracted inflammatory cells 
further release VEGF contributing to continuous vessel remodeling. The resulting 
imbalance of pro- and anti-angiogenic signaling within tumors creates an abnormal 
vascular network that is characterized by dilated, tortuous, and hyperpermeable ves-
sels. The physiological consequences of these vascular abnormalities are irregular 
blood flow and impaired oxygen delivery [104] resulting in a reduction in the efficacy 
of chemo- and radiotherapy. Since cancer cells are more resistant to hypoxia than 
normal cells, they undergo epigenetic changes in hypoxic conditions that promote 
their malignant phenotype and the epithelial-to-mesenchymal transition (EMT) [105]. 
HIF-1α-mediated production of several growth factors in cancer cells and the activa-
tion of oncogenes promote invasive growth and metastasis [106].  
At the cellular level, the endothelial cells lining tumor vessels have an irregular, dis-
organized morphology. Continuous VEGF-VEGFR2 signaling promotes contraction of 
the EC cytoskeleton and weakening of VE-cadherin junctions, and hence a loosening 
of EC associations [4]. Moreover, deregulated PDGFβ, Ang1/2, and TGF-β signaling 
in tumors impairs vessel coverage with perivascular cells and prevents a proper ves-
sel maturation and stabilization [107]. 
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A recent study revealed that PHD2 haplodeficiency induced tumor vessel normaliza-
tion [20]. The ECs of the tumor vasculature in PHD2 haplodeficient mice were lined in 
a single, tight and regular monolayer. In contrast to the ECs of wild type tumor ves-
sels, which were hyper-activated and exhibited loosened tight cell-cell contacts. The-
se changes in EC shape in PHD2 haplodeficient mice did not affect primary tumor 
growth, but improved the tumor perfusion and oxygenation. Moreover, this normal-
ized endothelial monolayer prevented a metastatic switch and prolonged the survival 
of PHD2 haplodeficient mice [20, 108].  
 
3.10 Sprouty proteins 
The founding member of the Sprouty (SPRY) protein family has been originally dis-
covered in a screen for genes in Drosophila that were responsible for modulating the 
developing trachea [109]. Drosophila SPRY (DSPRY) inhibited the RTK/Ras/ERK 
signaling downstream of different growth factors [110]. Based on sequence homology 
to Drosophila Spry, orthologs were identified in the mouse, human, chicken, zebrafish 
and frog (Xenopus laevis and Xenopus tropicalis) [109, 111-116]. Compared to 
DSPRY (63kDa), the vertebrate SPRY proteins are considerably smaller than the 
Drosophila homolog, with predicted molecular masses of 32–35 kDa. Similarity to the 
fly protein is restricted primarily to the cysteine-rich region (44–52% identity) termed 
the SPRY domain. Of the 22 cysteine residues found in DSPRY, at least 18 are pre-
sent in each vertebrate protein [8]. The SPRY domain also contains a highly con-
served motif Raf1-binding domain (RBD). The N-terminal half of the SPRY proteins 
contains a highly invariant tyrosine residue (Y) located in a short, conserved motif. 
Sprouty2 (SPRY2), one of four mammalian homologues, exhibits the highest se-
quence conservation across species; human SPRY2 is 97% homologous to mouse 
SPRY2, 85% to chick SPRY2 and 51%, in the cysteine-rich region, to DSPRY [111] 
(Fig. 9).  
SPRY2 plays a comparable role to DSPRY in regulating branching of the mammalian 
lung [114]. SPRY2 thereby functions as a negative regulator of embryonic lung mor-
phogenesis and growth downstream of FGF10 signaling [6]. 
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Figure 9. Structure of Drosophila and mouse Sprouty proteins. All Sprouty proteins contain a 
cysteine-rich SPRY2 domain at the C-terminus with a Raf1-binding domain RBD. The more divergent 
N-terminus harbors a highly invariant tyrosine residue located in a short conserved motif. The SPRY2 
gene product exhibits the highest sequence similarities across species including Drosophila SPRY [8]. 
 
3.10.1 Sprouty proteins and RTK signaling 
As negative-feedback loop regulator all Sprouty proteins are induced by the signaling 
cascade they target. Growth factor stimulation activates the Ras-ERK MAPK path-
way, which ends in the translocation of phosphorylated ERK to the nucleus, where it 
activates the transcription of target genes, one of which is Spry [8]. SPRY proteins 
specifically inhibit Ras–ERK MAPK signaling by RTKs, leaving the phosphoinositide 
3-kinase (PI3K) and other MAPK pathways unaffected [117, 118]. 
The conserved tyrosine residue of SPRY1 and SPRY2 is phosphorylated upon FGF 
and EGF signaling, SPRY4 phosphorylation is induced by FGF and insulin. The Src 
family of kinases is likely responsible for phosphorylation of SPRY at this conserved 
tyrosine, while Shp2 phosphatase is involved in dephosphorylating this critical resi-
due [119-122] (Fig. 10). 
Membrane localization of SPRY proteins is a conserved mechanism induced by RTK 
signaling. SPRY2 colocalized with microtubules and translocated to membrane ruf-
fles upon growth factor stimulation [123]. A subset of growth factor-activated SPRY 
proteins localize to membrane structures and interact with target proteins via their C-
terminus. Accordingly, SPRY2 harboring an R252D mutation fails to translocate to 
the plasma membrane [124], and ectopically-expressed C-terminal truncated ver-
sions of SPRY2 are unable to inhibit cell migration, cell proliferation and MAPK acti-
vation in response to diverse growth factors [125, 126].  
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Figure 10. The covalent modifiers of SPRY proteins. Sprouty function is controlled by covalent 
modification: predominantly phosphorylation and ubiquitination. The location of the binding and target-
ing for the Ser/Thr kinases is indicated. Two ubiquitin E3 ligases, Cbl, and SIAH2, bind to the N-
terminus of SPRY, whereas the SHP2 tyrosine phosphatase and Raf kinase bind to the cysteine-rich 
domain (CRD). It presently appears that covalent modifications that determine the activity and fate of 
SPRY localize to the N-terminus while the majority of binding localizes to the CRD [127]. 
 
3.10.2 Sprouty and FGF signaling 
FGF stimulation induces SPRY2 phosphorylation on Tyr55 by a Src-like kinase and 
on Y227 by a yet unknown kinase [119, 122, 128, 129]. Simultaneously, SPRY2 is 
dephosphorylated on the serines 112 and 115 by PP2A [10, 130]. A subgroup of 
SPRY2 translocates to the plasma membrane [10] and interferes with the RTK cas-
cade on several levels. Under certain conditions, SPRY binding to GRB2 is sufficient 
to inhibit FGF-induced activation of MAPK, while in others GRB2 association is not 
required [131, 132]. In addition, SPRY binding to SOS1 and potentially to Raf1 inhib-
its FGF-stimulated MAPK activation [8, 133]. SPRY binds RAF1, through its con-
served RAF1-binding domain (RBD). This interaction inhibits the phosphorylation and 
activation of RAF1, and thus, the subsequent activation of ERK1/2. In ATDC5 chon-
drocytes, FGF2 induced Spry gene expression through Ca2+- PLCγ dependent path-
ways [134]. Chelation of extra and intra-cellular calcium prevented SPRY1 induction, 
whereas SPRY2 expression exclusively depended on intra-cellular calcium. Further-
more, transfection of FGF-receptors lacking the PLCγ binding site only weakly in-
duced Spry1 and 2 expression. Finally inhibition of PLCγ repressed the activation of 
Spry1 and Spry2 expression [134].  
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3.10.3 Sprouty, EGF, VEGF and RTK independent signaling 
In contrast to their canonical function as negative feedback loop regulators of RTK 
signaling cascades the Sprouty proteins enhances EGF signaling in certain cellular 
settings [8, 9]. Upon growth factor stimulation the E3 ubiquitin ligase c-Cbl usually 
terminates EGF signaling via binding and ubiquitination of the EGF receptor. SPRY2 
interferes with this interaction and competes with the EGFR for c-Cbl-binding pre-
venting receptor internalization, thereby sustaining EGFR signaling [135-138]. 
SPRY2 binds the endocytic adapter CIN85 and inhibits the clustering of c-Cbl that is 
required for EGFR endocytosis and degradation [138]. Since other RTKs, such as 
FGFR are degraded via c-Cbl interaction it remains uncertain how Sprouty proteins 
discriminate between EGF and FGF signaling. It is believed that both EGF and FGF 
stimulated phosphorylation of SPRY2 Tyr55 while, only FGF significantly phosphory-
lated a conserved tyrosine (Y227) in the C-terminus of SPRY2 [129]. In addition, 
SPRY2 interferes with trafficking of activated EGFR to late endosomes [139]. 
In endothelial cells, VEGF binds to VEGF receptor (VEGFR) and activates MAPK via 
the phospholipase C gamma (PLCγ) and protein kinase C (PKC) pathway where 
PKC phosphorylates Raf1, thereby activating ERK/MAPK in a Ras independent 
manner [140, 141]. Although all SPRY isoforms carry a Raf1-binding domain (RBD) 
in their highly conserved C-terminal domain, only SPRY4 has been shown to directly 
bind Raf1 in a VEGF dependent manner, thus interfering with VEGF signaling [142] 
(Fig. 11). Typically, the regulation of SPRY2 expression and activity depends on 
RTK-MAPK signaling [8]. However, more and more RTK independent mechanisms 
are being described. In Fibroblasts, TGFβ1 increased SPRY2 degradation, and at the 
same time, also decreased its transcription [143]. Furthermore, TNFα downregulated 
SPRY2 at the level of translation [144]. Conversely, SPRY2 overexpression inhibited 
TNFα mediated apoptosis, suggesting that SPRY2 plays a role in controlling apoptot-
ic action of TNFα. 
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Figure 11. SPRY mechanisms of action in growth factor signaling pathways. (a) Signal transduc-
tion in the absence of SPRY. Upon ligand binding, RTKs can activate MAPK in a Ras-dependent 
manner via the adapter protein GRB2 and SOS1-mediated activation of Ras, Raf1, MEK, and eventu-
ally MAPK. Another conserved RTK pathway that can be activated is that mediated by PLCγ, which 
converts phosphatidylinositol [4, 5]-bisphosphate (PIP2) into two second messengers: inositol [1, 4, 5] 
trisphosphate (IP3) and diacylglycerol (DAG), leading to calcium (Ca2+) mobilization. Both DAG and 
Ca2+ activate PKC, which in turn phosphorylates Raf1, thus leading to MAPK activation. (b) SPRY-
mediated inhibition of the FGF signaling pathway. SPRY is serine phosphorylated on multiple residues 
in unstimulated cells and at least serines 112 and 115 are dephosphorylated by PP2A upon FGF 
stimulation. Also, SPRY phosphorylation at Y55 by a Src-like kinase and by an unknown kinase (X) at 
Y227 is required for SPRY to inhibit FGF-induced activation of MAPK. Under some conditions, SPRY 
binding to GRB2 is sufficient to inhibit FGF-induced activation of MAPK, while in others GRB2 associa-
tion is not required. Also, SPRY binding to SOS1 and potentially to Raf1 inhibits FGF-stimulated 
MAPK activity. (c) SPRY-mediated potentiation of the EGF signaling pathway. Upon EGF binding, 
SPRY is tyrosine phosphorylated and competes with EGFR for binding to c-Cbl. By interacting with c-
Cbl, SPRY becomes ubiquitinylated and eventually degraded, allowing for sustained EGFR signaling. 
(d) SPRY-mediated inhibition of the VEGF signaling pathway. The VEGFR signals via the PLCγ/PKC 
pathway. Upon VEGF activation, SPRY interacts with Raf1 via its RBD and inhibits activation of 
MAPK. Tyrosine phosphorylation of SPRY is not required for this activity. pY and pS denote phos-
phorylated tyrosine and serine residues, respectively. In this schematic, using SPRY2 as the repre-
sentative SPRY isoform, pY55 and pY227 represent the N- and C- terminal phospho-tyrosines [9]. 
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3.10.4 Hypoxia and SPRY2 
Hypoxia stabilizes Sprouty proteins in Hela cells and SPRY2 in colon carcinoma cells 
(LS174T). Under normoxic conditions SPRY2 is hydroxylated on proline residues 
18,144 and 160 by prolyl hydroxylase domain proteins 1-3 (PHD1-3). Upon proline 
phosphorylation SPRY2 interacts with Von Hippel-Lindau protein (pVHL). pVHL sub-
sequently ubiquitinates SPRY2 and targets it for degradation. Accordingly silencing 
of PHD1 or pVHL increase SPRY2 levels and its ability to inhibit FGF-induced 
ERK1/2 activity [145]. 
 
3.10.5 Sprouty proteins in the vasculature 
A genetic screen has revealed enriched SPRY2 mRNA in tube forming human micro-
vascular endothelial cells (HMVECs) versus proliferating HMVECs [146]. In a subse-
quent study overexpression of Sprouty1 and 2 inhibited FGF, VEGF and EGF in-
duced proliferation and differentiation of human umbilical endothelial (HUVEC) cells 
[10]. Expression of SPRY4 in endothelial cells inhibited FGF2- and VEGF-induced 
MAPK activity upstream of Ras. Furthermore, gene-transfer of Spry4 in the mouse 
embryo inhibited sprouting and branch formation of the yolk sac vasculature [147].  
The FoxO transcription factors are tumor suppressors and regulate endothelial cell 
homoeostasis. In liver endothelial cells Spry2 is a direct target of the FoxO transcrip-
tion factors. The Spry2 promoter contains several FoxO binding elements. According-
ly, Spry2 mRNA was significantly down regulated in FoxO knockout liver endothelial 
cells [148].  
In the rat carotid artery, endogenous Sprouty2 decreased immediately after balloon 
induced injury and then increased between 7 and 14 days. Exogenously expressed 
human SPRY2 inhibited growth and migration of vascular smooth muscle cells in 
vitro and neointima formation after blood vessel injury in vivo [149]. Accordingly, sup-
pression of SPRY2 and SPRY4 enhanced angiogenesis in a mouse model of hind 
limb ischemia [150].  
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3.10.6  Spry2 knockout phenotypes 
Despite the ubiquitous Sprouty expression in the vasculature, none of the Sprouty 
knockouts described exhibit an overt vascular phenotype.  
Sprouty2 null mice have been generated by two different groups [151, 152] and in-
vestigated in several studies yielding new information about the function of Sprouty2. 
Overall, Spry2 null mice show reduced body size and shortened life span. Loss of 
SPRY2 resulted in enteric nerve dysplasia leading to esophageal achalasia and in-
testinal pseudo-obstruction due to deregulated glial cell line-derived neurotropic fac-
tor (GDNF) resulting in ERK and AKT hyperactivation [152]. In another study, 
Sprouty2-deficient mice showed a higher incident of cleft palate than wild type mice. 
This process depended on increased palate mesenchymal cell proliferation via FGF 
signaling [153]. Shim et al. found that lack of Sprouty2 resulted in dramatic perturba-
tions in the organ of Corti cytoarchitecture. The mice suffered of severe hearing loss 
due to an additional pillar cell layer. This postnatal cell fate transformation in the audi-
tory epithelium was due to increased FGF8 signaling [151]. A further chapter was 
added by Klein et al. who discovered an additional tooth in the diastema of Spry2-null 
mice [154]. In subsequent study the authors showed that increased FGF signaling 
resulted in decreased apoptosis and increased proliferation [155]. Finally, loss of 
Sprouty2 partially rescues renal hypoplasia and stomach hypoganlionosis in Ret 
Y1062F mutant mice by regulating downstream signaling of the GDNF/RET complex 
[156]. 
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4 RATIONALE AND AIMS  
Over the last years, an enormous amount of knowledge with regard to formation of 
new vessels has been accumulated. However, the ultimate steps of angiogenesis, 
including tube stabilization and restoration of the barrier function, are still poorly un-
derstood. Furthermore, not only newly-formed vessels but also existing ones need to 
be actively maintained in order to preserve vascular integrity and tissue homeostasis 
[4, 47]. In that physiological situation, endothelial cells form a tight monolayer, resist 
apoptosis and remain quiescent (defined as reversible cell growth/proliferation arrest) 
even in the presence of angiogenic factors [2, 3].  
Thus the question of how endothelial cells process signals arising from increasing 
cell density to allow a switch from a proliferative, migratory phenotype to a quiescent, 
impermeable monolayer remains largely unanswered.  
Several surface molecules associated with adherens and tight junctions have been 
suggested to mediate cell-contact inhibition and vascular integrity via regulating intra-
cellular signaling cascades and transcription [4]. Endothelial cells mediate contact 
inhibition of growth at least in part, by cell cycle exit via inhibition of the MAPK 
ERK1/2, a major downstream target of FGF, VEGF and other angiogenic growth fac-
tors [5]. Therefore, potential negative regulators of this growth promoting signaling 
cascades are likely to play a central role in this feedback inhibition of cell growth. 
As potent antagonist of MAPK signaling, SPRY2 is a potential candidate for mediat-
ing endothelial cell quiescence. Several overexpressing studies [10, 126, 157] and 
SPRY2 knockout mice [151, 153-155] confirmed its potential as a negative regulator 
of several RTK-related signaling pathways. However, the endogenous expression 
pattern(s) of SPRY2 remain not well delineated, and it is unknown whether SPRY2 
function regulates endothelial quiescence. 
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The major aims of this thesis are 
 
(i) to assess regulation of SPRY2 expression in endothelial cells in vitro 
with respect to;  
a. cell-density  
b. hypoxia  
c. cell-cell contacts 
 
(ii) the generation of Spry2 knockout endothelial cells  
a. to investigate ERK1/2 phosphorylation in the presence and absence 
of SPRY2  
b. to investigate the potential role of SPRY2 in mediating contact inhi-
bition during the formation and maintenance of the endothelial mon-
olayer 
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5 MATERIALS AND METHODS 
5.1 Isolation of mouse aortic endothelial cells 
Mouse aortic endothelial cells (MAECs) were isolated from aortae of 8-10 weeks old 
C57BL/6 wild type male mice or Sprouty2 floxed female mice. Fibrin gels were pre-
pared by mixing 3 mg / ml of fibrinogen (Sigma,F4883) with serumfree DMEM (500 
ml DMEM (Biochrom AG, FG 0435) were complemented with 5 ml of non-essential 
amino acids (GIBCO®, 11140); 5 ml of Sodium Pyruvate (GIBCO® 11360), and 5 ml 
Pen-Strep (GIBCO® 15140)) and 300 µg / ml of thrombin (Sigma T4393) on ice. 24-
well plates were coated with 400 µl / well of the prepared fibrin gel and incubated for 
about half an hour at 37°C to allow polymerization. 
The excised aorta was cleaned by cutting off connective and fat tissue under the bin-
ocular. The Aorta was then cut in small rings by using sterile scalpels (Swann-
Morton, 0501), and the pieces were placed on top of the gel. Then the aortic pieces 
were overlaid by using another portion of fibrin gel. After gel had polymerized at 
37°C, 500 µl / well of pre-warmed EC growth media (serumfree DMEM that contained 
10 % FCS (Biochrom S0615), 100 µg / ml of ECGS (Millipore 02-102), and 0.1 u / ml 
of heparin (B. Braun 3511014)) was loaded to the wells. To protect the fibrin gel from 
degradation, 300 µg / ml of E-amino caproic acid (Sigma A-7824) diluted in PBS was 
added to all wells every other day. After 10 days of culturing, angiogenesis-like 
sprouts were observed under the microscope (Olympus1X71). The outgrown cells 
were harvested by pipetting up and down the fibrin gel. The gel-cell mixture was 
transferred to a six-well plate which had previously been coated with 0.1% gelatin 
gold (Carl Roth GmbH 4274.1), and 1 ml / well of EC growth media w/o Heparin was 
added. The next day, cells were washed once with warm PBS and new EC growth 
media was added. Confluent cells were split 1:2 by trypsinization by using TrypLETM-
Express (GIBCO®, 12605) and characterized with endothelial cell specific immuno-
fluorescent marker von Willebrand Factor (VWF, LabForce AG) (Fig. 12).  
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Figure 12. Isolation of mouse aortic endothelial cells (MAECs). The excised, cleaned aorta is cut 
in rings and placed on fibrin gel. The outgrown endothelial cells form a typical monolayer next to the 
aortic explant (upper panel). The subcultured cells express the endothelial specific von Willebrand 
Factor (lower panel). 
 
5.2 Cell culture and treatments  
For all experiments using MAECs, cell culture dishes were coated with 0.1% gelatin 
gold (Carl Roth GmbH 4274.1) for 20 minutes at 37°C. MAECs were maintained in 
DMEM (Biochrom FG435), complemented with 10% FCS (Biochrom S0615), 1% so-
dium pyruvate (GIBCO 15140), 1% non-essential amino acids (GIBCO 11140) and 
1% penicillin-streptomycin (GIBCO 15140). Human breast carcinoma cell line (HBL-
100) and human epithelial colorectal adenocarcinoma cells (Caco2) were cultured in 
RPMI 1640 (GIBCO 21875), complemented with 10% FCS (Biochrom S0615) and 
1% penicillin-streptomycin (GIBCO 15140). Cell numbers were assessed with a Nu-
cleoCounter® NC-100™ (Chemometec). MAECs were treated with one or more of 
the following growth factors, reagents, and inhibitors: FGF2 25 ng / ml (R&D Systems 
3139-FB/CF); recombinant mouse TNFα 10 ng / ml (RD 410-MT-010); MG132 5 µM 
(Calbiochem 474790), EGTA 2.5 mM (Calbiochem 324626), BAPTA-AM 10 µM (Mo-
lecular Probes B1205); human thrombin 1 u / ml (Sigma T4393); recombinant mouse 
VE-cadherin 2 µg / ml (RD 1002-VC); VE-cadherin blocking antibody 10 µg / ml (BD 
Pharmingen 555289); and U0126 5 µM (Promega V112A). To create a hypoxic envi-
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ronment cells were placed in a hypoxia incubator (Thermo Scientific Hera Cell 150) 
with 1% oxygen for 24 hours. Micrograph pictures of cells were taken with a digital 
camera (Olympus F-viewXS) and an inverted microscope (Olympus1X71). GFP ex-
pression was monitored using a U-LH100HG light source with a U-MWB2 filter 
(Olympus). 
 
5.3 Immunoblotting 
To extract protein, cells were washed twice with ice cold PBS and then harvested by 
scraping with a cell scraper (BD Falcon 353089) into 1 ml of ice cold PBS. The cell 
suspension was collected with a 1 ml pipette, transferred to a 2 ml Eppendorf tube, 
and then centrifuged for 5 minutes at 14,000 rpm at 4°C. The pellet was re-
suspended in RIPA buffer that contained a complete mini protease inhibitor (Roche 
11836153001) and a phosphatase inhibitor cocktail 2 (Sigma P5726) and then was 
lysed by using liquid nitrogen in four freeze-and-thaw-cycles. The sample was centri-
fuged for 15 minutes at 14,000 rpm at 4°C. The resulting supernatant was transferred 
to a new 1.5-ml Eppendorf tube and the protein concentration measured by using a 
BCA protein assay kit (Thermo scientific 23223). Equal amounts of protein were 
loaded on a 10% acrylamide-SDS gel. Separated proteins were transferred to a ni-
trocellulose membrane (Whatman BA85) by using a semidry blotting procedure, 
blocked for 1 hour at room temperature (RT) in Tris buffered saline (TBS) that con-
tained 5% skim milk powder (Sigma 70166). 
Membranes were washed once with TBS-tween (0.1%) and incubated overnight at 
4°C with one of the following primary antibodies: rabbit anti Sprouty2 1:4,000 (H-120, 
Santa Cruz sc-30049), rabbit anti Sprouty2 1:1,000 (abcam ab50317), rabbit anti 
pospho-ERK1/2 1:1,000 (Cell Signaling 9101), rabbit anti total-ERK1/2 1:1,000 (Cell 
Signaling 9102), rabbit anti FoxO1 1:1,000 (Cell Signaling 9462), rabbit anti FoxO3a 
1:1,000 (Cell Signaling 2497), rabbit anti phospho-FoxO1 (Thr24)/FoxO3a (Thr32) 
1:1,000 (Cell Signaling 9464), rabbit anti HIF-1α 1:1000 (Novus Biologicals NB100-
479) and mouse anti β-Actin 1:10,000 (Sigma A-5441). 
The next day, the membrane was washed three times in TBS-0.1 % tween and incu-
bated with a secondary antibody goat anti rabbit HRP 1:5,000 – 1:20,000 (Cell Sig-
naling 7074) or anti mouse HRP 1:80,000 (Cell Signaling 7076) for 1 hour at room 
temperature (RT). After another wash step, a chemiluminescent substrate that is 
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used for the detection of HRP (Thermo Scientific 34080) was applied to the mem-
brane, and then the membrane was incubated for 1 minute. The signal was detected 
with a CL-XPosure film (Thermo Scientific 34090), and the resulting bands were 
quantified by using ImageJ (Wayne Rasband, NIH, MD, USA). 
 
5.4 Oxygen sensing 
Changes in the oxygen saturation of cell cultures were measured in real time by us-
ing an SDR SensorDish reader (Presens). MAECs were plated on an Oxodish 24-
well plate (OD24) with integrated oxygen sensors (Presens 200000430). Oxygen 
saturation of the media was measured every 30 minutes and data was collected and 
analyzed by using SDR_v38 software (Presens) on a personal computer.  
 
5.5 mRNA extraction and quantitative real-time PCR 
To isolate RNA, cells were first harvested by scraping by scraping with a cell scraper 
and the RNA then isolated by using RNeasy kit (Qiagen 74106) according to direc-
tions in the manufacturer’s manual. The RNA was then reverse transcribed to cDNA 
by using the Taqman Kit (Roche Applied Biosystems N808-0234). The following pri-
mers were used for qRT-PCR:  
 
Spry2-fwd  (ATAATCCGAGTGCAGCCTAAATC)  
Spry2-rev  (CGCAGTCCTCACACCTGTAG) 
GAPDH-fwd  (TGTGTCCGTCGTGGATCTGA)  
GAPDH-rev  (CCTGCTTCACCACCTTCTTGA)  
 
The cDNA samples and the forward and reverse primers for the endogenous control 
gene (GAPDH) and the target gene (Spry2), together with SYBR green PCR master 
mix (Applied Biosystems 4385612) were loaded on a 96-well PCR reaction plate. Da-
ta was collected and normalized to GAPDH by running the relative quantitation pro-
gram with the 7500 real time PCR system (Applied Biosystems).  
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5.6 FoxO1/3 silencing  
3 million cells were transfected with one 2 µl of the following siRNAs: FoxO1 siRNA, 
FoxO3 siRNA, and siRNA negative control (Stealth RNAi™ siRNA Invitrogen 
1320003). Cell transfection was performed using a basic endothelial cells nu-
cleofector kit in a Nucleofector II device (Lonza) according to the manufacturer’s pro-
tocol. 
 
5.7 Electric cell-substrate impedance sensing 
Electrical resistance measurements were performed using an ECIS ZӨ apparatus 
(Applied Biopyhysics) in 8-well (0.8 cm2 / well) arrays with 40 (8W10E+) gold elec-
trodes with a diameter of 250 µm (Applied Biopyhysics). Each experiment was car-
ried out in duplicates. Before seeding the cells, each well was pre-incubated with se-
rum-free DMEM overnight. That was followed by a 20 minutes coating with 0.1% gel-
atin gold (Carl Roth GmbH 4274.1) and 0.9% sodium chloride in PBS followed by 
three wash steps with growth media. The arrays in the measurement station were 
then placed in an incubator (37°C, 5% CO2) to allow real-time monitoring. Total re-
sistance was measured at a frequency of 4 kHz. The initial baseline values were 
normalized to 1.  
 
5.8 Generation of Spry2 knockout cells  
800,000 Spry2 floxed MAECs were seeded on a 10 cm culture dish. The next day, 
the media was removed and a virus (100 MOI) that contained either Ade-CRE-GFP 
(Vector Biolabs 1045) or Ade-CMV-GFP (Vector Biolabs 1060) was added in 3 ml of 
growth media to the cells. After 6 hours, the media was removed, replaced by 10 ml 
of normal growth media, and then incubated at 37°C. Endothelial cells expressed 
GFP the following day. Down-regulation of Spry2 was assessed by using qRT-PCR 
and Western blot (Fig. 13). Steps that involved handling viruses or virus-transfected 
cells were undertaken in a level-2 biosafety hood (Skan VSB 90) in a certified cell 
culture laboratory.  
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Figure 13. Generation of Spry2 knockout MAECs(A) The aorta of floxed-Spry2 mice is excised and 
MAECs are isolated. (B, C) Virus that contains either Ade-CRE-GFP or Ade-CMV-GFP vectors is add-
ed to MAECs. (D) The introduced CRE recombinase excises Spry2 from the DNA. (E) qRT-PCR con-
firms efficient knockout of spry2. 
 
5.9 Proliferation assay  
20,000 cells per well were seeded in 6 replicates and then grown in 100 µl of growth 
media with 1% FCS in a 96-well plate both with and without 25 ng / ml of FGF2. After 
48 hours, 10 µl of alamarBlue® solution (Invitrogen DAL1100) was added for 3 hours. 
Fluorescence was measured (Ex 560; Em 590) by using a Spectramax M2 reader 
(Molecular Devices).  
 
39 
 
5.10 Permeability assay  
200,000 cells were re-suspended in 200 µl of complete growth medium supplement-
ed with 1% FCS both with and without 25 ng / ml of FGF2. Cells were then seeded in 
triplicate on cell culture inserts (3-µm pore size, Falcon 353096) and placed in 24-
well culture plates (Falcon 353047) that contained 600 µl of FGF2-free medium per 
well. After 48 hours, the inserts were moved to a new 24-well plate and 70 kDa FITC-
dextran was added to all inserts for 10 minutes. Fluorescence at Ex 585 nm and Em 
520 nm of the lower well was analyzed by using a Spectramax M2 reader. 
 
5.11 Statistical analysis 
All statistical tests were performed by using GraphPad Prism 5.04 for Windows® 
(GraphPad software, San Diego, CA, USA). We have used unpaired t-test to evalu-
ate differences between two groups. If there were more than two groups, we used 
one-way ANOVA, followed by a Newman-Keuls post-test. P<0.05 was considered 
significant. 
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6 RESULTS 
6.1 High cell density causes transient hypoxia and increases SPRY2 expres-
sion during the formation of the endothelial monolayer 
To investigate whether high endothelial cell density affects SPRY2 protein expres-
sion, mouse aortic endothelial cells (MAECs) were plated sparsely and grew to high 
cell density and confluence over a time period of 24 to 96 hours (Fig. 14A). After 24, 
48, 72 and 96 hours cells were analyzed for SPRY2 expression. SPRY2 protein lev-
els were low after 24 hours of culturing. After 48 hours SPRY2 expression increased 
markedly and reached a maximum between 72 and 96 hours after seeding (Fig. 
14B). Thus, SPRY2 protein expression increased with higher cell density. 
Conventional monolayer cultures are often hypoxic when incubated in an air / 5% 
CO2 atmosphere [158]. Thus, hypoxia that results from increased oxygen-
consumption during endothelial monolayer formation may correlate with high cell 
density and may upregulate SPRY2 expression. To investigate this hypothesis, we 
analyzed the expression of the hypoxia marker HIF-1α over a time period of 24 to 96 
hours. HIF-1α levels increased at 48 hours, dropped at 72 hours, and were undetect-
able after 96 hours of cell seeding (Fig. 14C). We then further substantiated these 
findings by measuring oxygen levels of sparsely-seeded cells directly and in real time 
over a period of 0-96 hours: Oxygen saturation decreased slightly after 24 hours 
(80% O2 saturation) and declined to a minimum between 48 and 72 hours after cell 
seeding (70% O2 saturation) compared to a control with no cells present (85% O2 saturation 
throughout the experiment) (Fig. 14D). These results demonstrate that increased 
SPRY2 expression after 48 hours of endothelial cells growing to confluence is ac-
companied by hypoxia and elevated HIF-1α expression. 
 
 
 
 
 
41 
 
 
 
Figure 14. High cell density and hypoxia increase SPRY2 expression during the formation of 
the endothelial monolayer. (A) Micrographs (scale bar 100 µm) of mouse aortic endothelial cells 
(MAECs) plated at sparse condition (3,000 cells / cm2) and grown for the indicated time. (B and C) 
Total SPRY2, HIF-1α, and β-Actin expression of samples collected at the indicated times were ana-
lyzed by Western blotting. (D) Real-time measurement of the oxygen consumption of MAECs growing 
to confluence (initially plated at sparse density; 3,000 cells / cm2). Results show representative of two 
independent experiments performed in duplicates.  
 
6.2 SPRY2 expression under normoxic and hypoxic conditions 
To investigate whether hypoxia really induces SPRY2 protein expression, we re-
duced oxygen consumption by starving the cells to reduce metabolism [158]. Re-
placement of the growth media by serum-free media after 24 hours reduced the oxy-
gen consumption of the endothelial cell cultures and restored basal oxygen levels 
after 48 hours. However, in the presence of serum, oxygen levels decreased further 
and reached a minimum level (65% O2 saturation) after 48 hours of cell seeding (Fig. 
15A). In parallel experiments, HIF-1α protein levels were measured before and after 
serum starvation. Indeed, HIF-1α protein levels dropped and were undetectable after 
changing growth media to serum-free conditions (Fig. 15B). Similarly, SPRY2 protein 
levels decreased but were still detectable in starved cells (Fig. 15B).  
To assess whether endothelial cells cultured in serum-free medium did not lose the 
potential to induce SPRY2 expression under hypoxia, cells were seeded at sparse or 
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confluent density, and serum-free endothelial cells were subjected to hypoxic (1% 
O2) and normoxic conditions in a hypoxia incubator. After 24 hours, SPRY2 in-
creased in cells under hypoxic conditions; this correlated with increased HIF-1α pro-
tein levels (Fig. 15C). Hypoxia, however, did not affect Spry2 mRNA levels (Fig. 
15D). Thus, it is likely that hypoxia regulates SPRY2 expression independent of HIF-
1α on a post-transcriptional level. 
 
 
 
Figure 15. SPRY2 expression under normoxic and hypoxic conditions. (A) Real time oxygen 
consumption of growing and quiescent cells (cells plated at confluence; 50,000 cells / cm2). After 24 
hours, either serum free or media with 10 % FCS was added for additional 24 hours to the cells (indi-
cated with a line). Results show representative of three independent experiments. (B) In parallel ex-
periments, cells were grown in 10% FCS for 24 hours and then either collected (FCS+) or starved for 
24 hours (FCS-). Total cell lysates were assessed for HIF-1α, SPRY2 and β-Actin expression. Three 
independent experiments, normalized to β-Actin expression, are summarized in a graph that shows 
densitometric quantification of the bands (**P<0.01). (C) MAECs were grown for 24 hours and then 
starved and grown under either hypoxic (1% O2) or normoxic (21 % O2) conditions. Total lysates were 
analyzed for HIF-1α, SPRY2, and β-Actin expression. Three independent experiments, normalized to 
β-Actin expression, are summarized in a graph that shows densitometric quantification of the bands 
(**P<0.01). (D) mRNA was collected from cells grown under either hypoxic (1% O2) or normoxic (21 % 
O2) conditions and analyzed for SPRY2 expression by using qRT-PCR. Values were normalized to 
GAPDH (n=4).  
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6.3 Density dependent SPRY2 expression in serum deprived MAECs 
To investigate, whether SPRY2 protein levels remained elevated in dense compared 
to sparse starved cultures, we seeded cells at different cell numbers (Fig. 16A), 
starved for 24 hours and assessed for SPRY2 protein expression. Sparsely plated 
cells (1,500 – 6,000 cells / cm2) expressed SPRY2 protein at very low levels. Sub-
confluently plated cells (12,000 – 25,000 cells / cm2) increased SPRY2 protein mark-
edly (40 fold and 66 fold, respectively). Plating 50,000 cells / cm2 lead to the for-
mation of a confluent monolayer and induced SPRY2 protein 74 fold as compared to 
sparsely plated cells at 1,500 cells / cm2 (Fig. 16B). We therefore hypothesized that 
in starved cells, SPRY2 might be stabilized at elevated level independent of hypoxia 
via another mechanism such as cell-cell contacts since SPRY2 protein levels re-
mained elevated in dense serum-free but normoxic cultures (Fig. 16B).  
Next we assessed, whether starved confluent cells exhibit increased Spry2 mRNA 
transcription. Indeed, Spry2 mRNA levels were moderately enhanced (two fold) in 
confluent (50,000 cells / cm2) compared to sparse cells (3,000 cells / cm2). (Fig. 
16D). In order to directly compare the Spry2 mRNA to the protein levels, we analyzed 
the same lysates for SPRY2 protein expression. The densitometric quantification of 
the Western Blot bands revealed a 70 fold increases of SPRY2 protein in confluent 
cells (50,000 cells / cm2) as compared to sparsely plated cells (3,000 cells / cm2) 
(Fig. 16D). Taken together, these results suggest that high cell density increases 
SPRY2 levels via transcriptional and post transcriptional mechanisms. The post tran-
scriptional part thereby seems to be more prominent.  
We then asked whether the observed cell-density-dependent regulation is restricted 
to MAECS. Therefore, we assessed SPRY2 expression in a human breast carcinoma 
cell line (HBL-100) and a human epithelial colorectal adenocarcinoma cells (Caco2), 
which were plated at different cell densities. Although, both cell lines exhibited a 
monolayer-like morphology and exhibited partial contact inhibition, they grew to very 
high densities (100,000 cells / cm2). SPRY2 expression increased with higher cell 
density in both cell lines HBL-100 and Caco2 (Fig. 17), suggesting that density in-
duced SPRY2 expression is a not a unique feature of MAECs. 
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Figure 16. Starved confluent endothelial cells express high SPRY2 protein levels. (A) Micro-
graphs (scale bar 100 µm) of MAECs plated at different cell numbers. (B) Western blot of SPRY2 total 
protein. Equal loading was confirmed by reprobing the membrane with the anti β-Actin antibody. Three 
independent experiments, normalized to β-Actin expression, are summarized in a graph that shows 
densitometric quantification of the bands. The values shown are means +/- s.e.m.; ***P<0.001 vs. 
1,500 cells / cm2. (C, D) A confluent MAEC culture was analyzed for SPRY2 expression by immunob-
lotting (C, left column) before plating the cells at sparse or confluent conditions. After 24 hours, cells 
were lysed (C, right column) or starved for another 24 hours. (D) After starvation, cells were analyzed 
for SPRY2 expression by immuoblotting and qRT-PCR. The values were normalized to GAPDH +/- 
(qRT-PCR) or β-Actin (immunoblotting) s.e.m.; ***P<0.001; ****P<0.0001; n=3. 
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Figure 17. SPRY2 expression increases with higher cell density in tumor cell lines. Micrographs 
(scale bar 100 µm) of Caco2 (A) and HBL-100 cells (B) plated at different cell number. SPRY2 protein 
expression was analyzed by immunoblotting. Equal loading was confirmed by reprobing the mem-
branes with the anti β-Actin antibody. 
 
6.4 Cell density increases SPRY2 expression independent of the FoxO1/3 
transcription factors 
Cell confluence increased SPRY2 partly via transcription (Fig. 16B). Since the Spry2 
promoter contains several FoxO binding elements [148], we asked whether the FoxO 
transcription factors may upregulate Spry2 transcription at high cell density. 
Dephosphorylated FoxO1 predominantly locates to the nucleus and shows increased 
transcriptional activity [159]. We therefore tested, whether the FoxO1 phosphorylation 
depended on cell density. Indeed, the relative FoxO1 phosphorylation levels de-
creased with higher cell density suggesting that confluent cell exhibited increased 
FoxO transcriptional activity (Fig. 18A). Silencing of FoxO1 and 3 mRNA effectively 
decreased FoxO1/3 protein levels (Fig. 18B). Surprisingly, FoxO1/3 knockdown did 
affect neither SPRY2 protein (Fig. 18B) nor Spry2 mRNA levels (Fig. 18C) suggest-
ing that transcription factors others than FoxO1/3 upregulated Spry2 mRNA and 
SPRY2 protein levels at high cell density. 
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Figure 18. Cell density increases SPRY2 expression independent of the transcription factors 
FoxO1 and FoxO3. (A) MAECs were plated at different cell number and analyzed for Foxo1 phos-
phorylation and total protein expression. Equal loading was confirmed by re-probing the membranes 
with the anti β-Actin antibody. The relative FoxO phosphorylation levels were analyzed by densitomet-
ric quantification of the FoxO Western Blot bands of two independent experiments. (B, C) Immunoblot-
ting (B) and qRT-PCR (C) revealed that SPRY2 expression was not affected by FoxO1/3 silencing. 
 
6.5 Cell-cell contacts stabilize SPRY2 protein levels in confluent cells 
To exclude the possibility that the increase in SPRY2 protein depends on factor(s) 
secreted by MAECs into the culture medium that would induce SPRY2 expression in 
an autocrine manner, conditioned medium from confluent MAECs cultures was sup-
plied to a sparse culture of MAECs and vice versa. The amount of SPRY2 protein 
was compared after 6 h. Conditioned medium of confluent cells did not induce 
SPRY2 protein expression and vice versa (Fig. 19A).  
Thrombin and TNFα both interfere with cell-cell contacts and increase endothelial 
permeability [160, 161]. We therefore tested, whether Thrombin and TNFα affect 
SPRY2 protein expression in confluent cells. A clear decrease in SPRY2 protein was 
detected after 6 hours treatment of confluent cells with Thrombin as well as with 
TNFα (Fig. 19B). In addition, TNFα reversibly decreased the total normalized electri-
cal resistance of the confluent MAEC monolayer (Fig. 19C). Moreover, TNFα in-
creased the permeability of the endothelial monolayer to 70 kDa FITC-Dextran con-
firming that TNFα disturbed cell-cell contacts (Fig. 19D). Taken together, these ob-
servations strongly support the perception that SPRY2 protein levels are positively 
regulated by cell-cell contacts. 
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Figure 19. Confluency stabilizes SPRY2 protein via cell-cell contacts rather than by soluble 
factors. (A) The supernatant of a confluent cell cultures was collected 24 after starvation and added 
either to sparse or confluent cells. At the same time the supernatant of sparse cells was collected and 
added either to confluent or sparse cells. After 6 hours the cells were lysed and assessed for SPRY2 
and β-Actin expression. (B) MAECs were plated at confluence, starved next day for 24 hours and then 
treated with thrombin (1 unit / ml) or TNFα (10 ng / ml) for 6 hours. The lysates were then analyzed by 
Western Blot for SPRY2 expression. Equal loading was confirmed by re-probing the membranes with 
the anti β-Actin antibody. (C) Cells were plated at confluence, and total resistance was measured in 
real time by ECIS. When cells reached a steady plateau in resistance (resistance = 1), either TNFα 
(10 ng / ml)  or PBS was added to the cells. After 60 hours new media was added to all cells. (D) The 
change of the permeability of the monolayer in the presence of TNFα. Cells were seeded at conflu-
ence on a well insert. TNFα (5 and 50 ng / ml) or PBS was then added to the cells overnight. Next 
day, 70 kDa FITC-Dextran was added for another 24 hours. The permeability of the monolayer was 
then evaluated by measuring fluorescence of the lower well. The values obtained for the controls with-
out TNFα were normalized to 1. Bars show values of triplicates as fold change of control +/- SD; 
***=p<0.001. 
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6.6 Disruption of calcium dependent cell-cell contacts decreases SPRY2 pro-
tein expression 
In order to further examine the kinetics of SPRY2 regulation by cell-cell contacts, we 
used ethylene glycol tetra acetic acid (EGTA) to chelate extracellular calcium and to 
disrupt calcium dependent cell-cell contacts [162].  
The addition of EGTA to confluent MAECs resulted in the formation of gaps between 
cells after 30 minutes and in a complete detachment from each other after 3 hours 
(Fig. 20A). Replacement of EGTA with new media restored the monolayer after 24 
hours of incubation. In parallel experiments, treatment with EGTA completely elimi-
nated SPRY2 expression after 0.5 and 3 hours of EGTA treatment (Fig. 20B). The 
restoration of the monolayer by new media also restored SPRY2 protein to the levels 
seen prior to EGTA treatment. We then measured the electrical resistance of the con-
fluent endothelial monolayer during EGTA treatment by electrical cell impedance 
sensing (ECIS). The electrical resistance dropped markedly after the addition of EG-
TA and then returned to basal levels (resistance prior the addition of EGTA) within 48 
hours after the addition of new media. This result demonstrated that the effect of 
treatment with EGTA was reversible and did not damage endothelial cell viability (Fig. 
20C). Of note, chelation of intracellular calcium with Bapta-AM did not affect SPRY2 
protein levels (Fig. 20D), and neither EGTA nor Bapta-AM affected Spry2 mRNA lev-
els (Fig. 20E). These findings indicate that density-dependent SPRY2 protein ex-
pression depends on intact cell-cell contacts and is independent of the level of intra-
cellular calcium.  
VE-cadherins are the predominant components of endothelial adherens junctions 
[54, 56, 163] and interact with cadherins of neighboring cells in a homophilic manner 
[57]. These adhesive complexes strictly depend on extracellular calcium [59, 162]. 
Therefore, VE-cadherin is a candidate molecule for the regulation of SPRY2 protein 
expression in confluent cells. In order to investigate whether VE-cadherin directly 
modulates SPRY2 expression we used a VE-cadherin blocking antibody [164] and 
soluble recombinant mouse VE-cadherin. Interestingly, the VE-cadherin antibody (10 
ug / ml) exclusively decreased SPRY2 protein levels when added to confluent cells, 
whereas in sparse cells no effect could be observed (Fig. 21A). In contrast, increased 
VE-cadherin blocking antibody concentration (100 µg / ml) seems to have a reverse 
effect: Preliminary experiments revealed that SPRY2 protein levels decreased when 
cells were plated in the presence of 100 µg / ml of the VE-cadherin blocking antibody 
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(results not shown). Finally, preliminary results revealed that the treatment of cells 
with soluble recombinant VE-cadherin decreased SPRY2 protein in both, sparse and 
dense cells. Taken together, these preliminary results suggest that VE-cadherin 
somehow modulates SPRY2 expression (Fig. 21B). However, the exact regulation 
mechanism remains elusive, since it is not clear how the VE-cadherin antibody and 
the soluble VE-cadherin protein interact with the endogenous VE-cadherin in reality. 
 
 
 
50 
 
Figure 20. SPRY2 protein expression depends on an intact endothelial monolayer. (A, panels 1-
3) Micrographs (scale bar 100 µm) of MAECs plated at confluence and treated with PBS (the control) 
or EGTA for the indicated time. (A, panel 3) After 3 hours, EGTA was replaced by fresh growth media, 
and cells were grown for an additional 24 hours. (B) SPRY2 expression after EGTA treatment. Cells 
were collected after the indicated incubation time with PBS or EGTA or 24 hours after replacement of 
EGTA with fresh media (3.0 + 24). The membranes were reprobed with β-Actin. (C) Cells were plated 
at confluence, and total resistance was measured in real time by ECIS. When cells reached a steady 
plateau in resistance (baseline), either EGTA or PBS was added to the cells. After 8 hours new media 
was added to all cells and the time point was set to zero. (D) Cells were treated with either EGTA or 
BAPTA-AM for 3 hours and analyzed for SPRY2 expression and β-Actin. (E) In parallel experiments, 
total RNA was isolated from cells that had been treated with EGTA, BAPTA-AM, or PBS. Spry2 mRNA 
levels then were determined by using qRT-PCR and normalized to GAPDH. The values shown are 
means +/- s.e.m.; n=3. 
 
 
 
Figure 21. VE-cadherin affects SPRY2 protein levels. (A) Sparse and confluent cells were incubat-
ed with anti-VE-cadherin antibody (10 µg / ml) for 6 hours and analyzed for SPRY2 protein expression 
by immunoblotting. (B) Recombinant VE-cadherin protein (+; 2.5 µg / ml) or BSA (-; 2.5 µg / ml) was 
added to sparse or confluent cells for 6 hours prior toSPRY2 detection by Western blotting. Both 
membranes were reprobed with β-Actin. 
 
6.7 High cell density induces SPRY2 and correlates with decreased ERK1/2 
phosphorylation 
To monitor whether ERK1/2 activity is affected by confluence in MAECS, we com-
pared ERK1/2 phosphorylation in sparse and confluent cells in response to FGF2 
stimulation. Sparse and confluent un-stimulated cells displayed no ERK1/2 activity. 
Stimulation of sparse cells with FGF2 for 3, 9 and 24 hours induced MAPK phos-
phorylation at the time points measured. Stimulation of confluent cells with FGF2 
strongly increased ERK1/2 phosphorylation after 3 and 9 hours (Fig. 22A1). However 
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after 24 h, the activity decreased markedly and was significantly lower in confluent 
compared to sparse cells (Fig. 22A2). These expected observations are in line with 
the results of Vinals et al. obtained in murine lung endothelial cells [5]. SPRY2 is a 
well-established modulator of MAPK activity [10, 117] and might therefore inhibit 
ERK1/2 activity in confluent cells. As expected, FGF2 treatment also increased 
SPRY2 protein levels. It was interesting to see that this increase in SPRY2 protein 
expression was much more prominent in confluent cells than in sparse cells (Fig. 
22B). To point out the reverse correlation of SPRY2 expression and ERK1/2 phos-
phorylation, we compared SPRY2 protein expression and ERK1/2 phosphorylation 
after 24 hours of FGF2 stimulation. In sparse cells, high ERK1/2 phosphorylation lev-
els were detected along with low SPRY2 protein levels. Vice versa, confluent cells 
expressing SPRY2 at high levels displayed low ERK1/2 phosphorylation levels (Fig. 
22C). Of note, FGF2-increased SPRY2 protein expression in confluent cells and to a 
lesser amount also in sparse cells, suggesting that cell density augmented FGF2-
induced SPRY2 expression in confluent cells. 
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Figure 22. In confluent endothelial cell cultures SPRY2 inhibits ERK1/2 activity. (A1) Cells were 
plated at sparse or confluent conditions, starved for 24 hours and then stimulated with FGF2 (25 ng / 
ml) or PBS for the indicated time. Cell lysates were analyzed for ERK1/2 phosphorylation and total 
protein expression. (A2) Relative phosphorylation levels of ERK1/2 were measured in sparse and 
confluent cells that had been treated with FGF2 for the indicated amount of time. Values were normal-
ized to the corresponding control at 3 hours. The values shown are means +/- s.e.m.; ** P<0.01; n=3. 
(B) We analyzed SPRY2 expression in sparse or confluent cells that had been treated with FGF2 (25 
ng / ml) or PBS for 3, 9 and 24 hours. (C) Reverse correlation between SPRY2 expression and 
ERK1/2 phosphorylation after 24 hours of FGF2 stimulation.  
6.8 Spry2 knockout increases FGF2-induced ERK1/2 signaling  
We then used Spry2fl/fl MAECs to generate Spry2 knockout cells to further explore 
the role of SPRY2 and MAPK activity in confluent endothelial cells. Spry2-/- and 
Spry2fl/fl showed equal GFP expression 24 hours after adenoviral transfection with 
Ade-CRE-GFP and Ade-CMV-GFP vectors (Fig. 23A). Spry2 mRNA knockout was 
efficient and stable for at least 5 passages after the transfection with Ade-CRE-GFP 
(Fig. 23B). Immunoblotting confirmed that SPRY2 protein could not be detected in 
the CRE-transfected cells (Fig. 23C). No evident phenotypic differences could be ob-
served between Spry2-/- and Spry2fl/fl MAECS during the normal culturing procedure. 
Spry2-/- and Spry2fl/fl MAECs were then plated at confluence, starved, and stimulated 
with FGF2 for 24 hours. The cells were then lysed and assessed for ERK1/2 phos-
phorylation and SPRY2 protein expression (Fig. 24A). 
 
 
 
Figure 23. Spry2 knockout MAECs. (A) GFP expression 24 hours after transfection with either Ade-
CRE-GFP (Spry2-/-) or the corresponding control virus Ade-CMV-GFP (Spry2fl/fl) (scale bar 100 µm). 
(B, C) Efficient knockout of Spry2 was confirmed by using qRT-PCR (Error bars show mean +/- s.e.m.; 
***P<0.001; n=3) (B), and immunoblotting (C). 
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SPRY2 protein was absent in Spry2-/- cells. Spry2fl/fl cells expressed SPRY2 both with 
and without FGF2 stimulation. However, after 24 hours of FGF2 stimulation, SPRY2 
significantly increased in Spry2fl/fl cells. Next we asked, whether Spry2-/- MAECs ex-
hibited increased ERK1/2 phosphorylation. Indeed, in Spry2-/- cells, FGF2-induced 
ERK1/2 phosphorylation levels doubled compared to those in Spry2fl/fl cells, while 
ERK1/2 phosphorylation was absent without stimuli in both cell types (Fig. 24B). 
These results validate that knockout of Spry2 increased FGF2-mediated ERK1/2 
phosphorylation and that SPRY2 inhibits FGF2-induced ERK1/2 activity in confluent 
Spry2fl/fl MAECs. Although the Spry2-/- cells exhibited increased ERK1/2 signaling 
upon FGF2 treatment, the cells did not show any phenotypic alterations. This obser-
vation might be due to the fact that the cells were able to form a mature monolayer 
prior the angiogenic stimulus. 
 
 
 
Figure 24. Loss of SPRY2 increases FGF2-induced ERK1/2 phosphorylation. Spry2fl/fl and Spry2-/- 
MAECs were seeded at confluence, starved for 24 hours and then stimulated with FGF2 (25 ng / ml) 
or PBS for 24 hours before lysis and immunoblotting. (A) Densitometric quantification of SPRY2 levels 
of Spry2fl/fl MAECs were normalized to β-Actin. Bars show values +/- s.e.m; ** = p<0.01; n=3. (B) 
Phosphorylation of ERK1/2 in Spry2fl/fl and Spry2-/- MAECs with and without FGF2 (25 ng / ml). The 
membrane was reprobed for total-ERK1/2. Phosphorylation levels were quantified after 24 hours of 
FGF2 stimulation of Spry2fl/fl and Spry2-/- MAECs. Bars show values as fold change of FGF2-
stimulated Spry2fl/fl cells. +/- s.e.m.; **P<0.01; n=3. 
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 We therefor decided to plate the cells together with FGF2. To provoke FGF2 specific 
effects on the endothelial cells we used serum reduced growth media with 1% in-
stead of 10 % FCS. We then analyzed SPRY2 protein expression under these condi-
tions. As expected, reducing the serum content of the growth media also decreased 
SPRY2 protein expression. This reduction in SPRY2 protein expression, however, 
was not observed when the cells were cultured with 1% FCS in the presence of 
FGF2 (Fig. 25).  
 
 
 
Figure 25. SPRY2 expression of serum reduced cultures in the presence and absence of FGF2. 
Cells were plated at sparse or confluent conditions in the presence of 1% and 10 % serum without 
FGF2 and 1% serum with FGF2 (25 ng / ml) and then grown for 24 h. SPRY2 protein expression was 
analyzed by immunoblotting. Equal loading was confirmed by reprobing the membranes with the anti 
β-Actin antibody. 
 
6.9 Spry2 knockout results in loss of contact inhibition and endothelial mono-
layer integrity in the presence of FGF2 
To evaluate the role of SPRY2 in the formation of the endothelial monolayer, we 
seed Spry2-/- (knockout) and Spry2fl/fl (wild type) MAECs at confluence in the pres-
ence or absence of FGF2. We observed that Spry2-/- MAECs grown for 48 hours in 
the presence of FGF2, were incapable of forming a mature monolayer and displayed 
an elongated, angiogenic phenotype with longitudinal gaps between the cells and 
little cell-cell contacts (Fig. 26B). In contrast to the latter results, Spry2fl/fl MAECs 
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formed a regular cobblestone-type cell monolayer with only a few elongated cells 
(Fig. 26A). FGF2 was required to disturb layer formation in Spry2-/- MAECs, because 
without FGF2 inclusion, Spry2-/- and Spry2fl/fl cells both formed a regular mature 
monolayer (Fig. 26A, B).  
 
 
 
Figure 26. Spry2-/- MAECs grown to high cell densities are incapable of forming a cobblestone 
shaped monolayer. (A and B) Micrographs (scale bar 100 µm) that show Spry2fl/fl (A) and Spry2-/- (B) 
cells plated at confluence and then grown for 48 hours in the presence of 1% FCS both with and with-
out FGF2 (25 ng / ml). Magnification (scale bar 50 µm) of the FGF2-treated Spry2fl/fl and Spry2-/- cells 
is also shown. 
 
To further characterize the perturbed endothelial monolayer formation by Spry2-/- 
cells, we analyzed proliferation and permeability. Cell numbers increased significantly 
in Spry2-/- MAECs as compared to Spry2fl/fl MAECs after 48 hours of FGF2-
stimulation (Fig. 27A). Again, no difference was observed between Spry2-/- and 
Spry2fl/fl when cells were grown without FGF2. Importantly, the monolayer formed by 
Spry2-/- cells exhibited significantly increased permeability against 70 kDa FITC-
Dextran in the presence of FGF2, while no difference was observed in cells without 
FGF2 (Fig. 27B).  
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Figure 27. Spry2-/- MAECs show increased proliferation and are incapable of forming a func-
tional and impermeable endothelial monolayer in the presence of FGF2. (A) Changes in the 
numbers of Spry2fl/fl and Spry2-/- cells were measured by using alamarBlue assay. Cells were plated at 
90% confluence and grown for 48 hours in the presence of 1% FCS both with and without FGF2 (25 
ng / ml). Then alamarBlue was added and the change in fluorescence measured after 3 hours. The 
values obtained for the controls without FGF were normalized to 1. Bars show values as fold change 
of control +/- s.e.m; **** = p<0.0001; n=4. (B) The change of the permeability of Spry2fl/fl and Spry2-/- 
monolayer in the presence of FGF2. Cells were seeded at confluence on a well insert in the presence 
of 1% FCS with and without FGF2 (25 ng / ml). The permeability of the monolayer to 70 kDa FITC-
Dextran after 10 min was evaluated by measuring fluorescence of the lower well. The values obtained 
for the controls without FGF were normalized to 1. Bars show values as fold change of control +/- 
s.e.m; ***=p<0.001; n=4. 
 
6.10 Inhibition of ERK1/2 signaling restores the wild type monolayer morphol-
ogy of Spry2-/- MAECs 
Next we asked whether inhibiting the MAPK ERK1/2 pathway could rescue disturbed 
endothelial monolayer formation of Spry2-/- cells. We therefore plated Spry2fl/fl MAECs 
and Spry2-/- MAECs in the presence or absence of U0126. After 1 hour, FGF2 or 
PBS (control) was added and cells were grown for 48 hours. Again, Spry2-/- MAECs 
showed a highly angiogenic phenotype in the presence of FGF2. However, when 
cells were pre-incubated with U0126 before adding FGF2, the wild type cobblestone 
phenotype was restored (Fig. 28A).  
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To demonstrate the efficacy of ERK1/2 inhibition by U0126, samples were collected 4 
hours after addition of the inhibitor and analyzed by immunoblotting. In the absence 
of U0126, FGF2 induced ERK1/2 phosphorylation in Spry2fl/fl and Spry2-/- MAECs 
(Fig 28B1). Again, the FGF2-induced ERK1/2 phosphorylation was more prominent 
in Spry2-/- MAECs (Fig. 28B2). When cells were grown in the presence of U0126, 
ERK1/2 activity was efficiently inhibited in Spry2fl/fl and Spry2-/- MAECs. Interestingly, 
SPRY2 expression depended on ERK1/2 activity, since in Spry2fl/fl MAECs, U0126 
reduced SPRY2 protein expression (Fig. 28B1).  
HIF-1α expression increases endothelial barrier permeability [165] and interferes with 
tight- and adherens junctions [166]. Since HIF-1α expression can be regulated by 
growth factors independent of hypoxia [167], we asked whether Spry2-/- MAECs 
showed enhanced HIF-1α expression in the presence of FGF2. FGF2 markedly in-
creased HIF-1α expression (Fig. 28C). However, no significant difference could be 
observed between Spry2fl/fl and Spry2-/- MAECs, suggesting that FGF2-induced HIF-
1α expression is not affected by SPRY2. Of note, pretreatment of the cells with the 
ERK1/2 inhibitor U0126 prevented FGF2-induced HIF-1α expression in Spry2fl/fl and 
Spry2-/- MAECs, suggesting that FGF2 increased HIF-1α expression via ERK1/2 (Fig. 
28C). Although the overall expression of HIF-1α was not affected by Spry2 knockout, 
we cannot rule out that SPRY2 controls HIF-1α activity and thereby maintains vascu-
lar integrity. 
Altogether these findings show that SPRY2, as a regulator of ERK1/2 activity, is in-
dispensable for endothelial cells to properly form a monolayer and maintain barrier 
integrity in the presence of FGF2. We feel that expression SPRY2 is especially im-
portant in the early phase of the monolayer formation. 
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Figure 28. Inhibition of ERK1/2 rescues the wild type endothelial monolayer morphology. (A) 
Micrographs that show Spry2fl/fl and Spry2-/- cells plated at confluence in the absence or presence of 
FGF2 (25 ng / ml) and then grown for 48 hours. Where indicated, cells were incubated with U0126 (5 
µM) 1 hour prior the addition of FGF2 (scale bar 100 µm). (B1) MAECs were plated at confluence in 
the presence or absence of FGF2 both with and without pre-incubation with U0126 (5 µM). Cells were 
collected 4 hours after seeding and then analyzed by immunoblotting. (B2) Densitometric quantifica-
tion of the ERK1/2 phosphorylation levels of B1. Bars show values as fold change of FGF2-stimulated 
Spry2fl/fl cells. +/- s.e.m.; **P<0.01; n=3. (C) MAECs were plated at confluence in the presence or ab-
sence of FGF2 both with and without 1 hour pre-incubation with U0126 (5 µM). Cells were collected 4 
hours after seeding and then analyzed by immunoblotting. 
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7 DISCUSSION 
The establishment of a mature, organized vascular network is fundamental for tissue 
homeostasis. Therefore, the formation of new vessels (angiogenesis) is an essential 
physiological process for embryologic development, organ growth, and tissue repair.  
During angiogenesis, a concerted action of hypoxia and growth factors induce vascu-
lar cell proliferation, migration and lumen formation [11, 19, 24, 84]. Once primary 
vessels have formed, endothelial cells shift their response from proliferation and mi-
gration to vessel maturation and stabilization giving rise to new, functional blood ves-
sels that are able to control permeability and supply the newly vascularized areas 
with oxygen and nutrients. In this state, endothelial cells form a tight monolayer, re-
sist apoptosis and remain quiescent even in the presence of pro angiogenic factors 
[2, 3]. The balance between quiescence and angiogenesis is tightly regulated at the 
molecular level and results in a tissue-specific, structured, hierarchically organized 
and functional vascular tree [105]. Loss of vascular integrity and dysregulated angio-
genesis is a hallmark of various pathologies including cancer, inflammatory disorders, 
atherosclerosis and age-related macular degeneration [168, 169].  
It is therefore important to understand how cells precisely control and restrict signal-
ing events when vascular integrity has to be maintained. On the other hand endothe-
lial cells need to keep the capability to proliferate and migrate in situations, where 
neovascularization is urgently needed. This thesis adds to the understanding of how 
endothelial cells can react to growth factor stimuli in respect to their current situation 
(sparse vs. confluent), and provide new insights into one of the last steps of angio-
genesis: the formation and maintenance of the endothelial monolayer. 
The Sprouty (SPRY) family of proteins is a highly conserved group of negative feed-
back loop modulators which control MAPK-signaling in endothelial cells [9, 10]. Our 
results show a novel cell density-dependent upregulation of SPRY2 in mouse aortic 
endothelial cells. We further demonstrate that SPRY2 contributes to the establish-
ment of endothelial quiescence and barrier integrity via inhibiting the FGF2-ERK1/2 
signaling. Accordingly, ablation of SPRY2 resulted in de-regulated FGF2-ERK1/2 
signaling and disturbed endothelial monolayer formation through loss of contact inhi-
bition and barrier integrity. 
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7.1 SPRY2 expression increases with higher cell density  
Results of this thesis reveal a novel mechanism whereby Sprouty2 is upregulated in 
a cell-density-dependent manner during formation of the endothelial monolayer. 
SPRY2 exclusively acts as an adaptor protein without any enzymatic activity [127]. 
Therefore, cells have restricted possibilities to control SPRY2 function: by regulating 
its abundance [143-145], its localization [10, 123], and/or its post-transcriptional 
modifications [119, 126, 170]. Here we show, that in primary endothelial cells, SPRY2 
is regulated in a previously unknown cell-density dependent fashion: Sparse cell cul-
tures express low SPRY2 protein levels (Figs. 14, 16), which may allow endothelial 
cell proliferation, migration, and tube formation during angiogenesis and wound clo-
sure [7, 10]. In dense cell cultures, SPRY2 expression is highly elevated (Figs. 14, 
16), which may inhibit endothelial proliferation and, thus, maintain vascular integrity 
and quiescence. Indeed, ablation of SPRY2 in confluent cells increases cell prolifera-
tion and the permeability of the endothelial monolayer (Fig. 27). In accord with our 
findings, Zhang et al. (2005) showed in vivo that SPRY2 protein decreased in the 
vasculature after an injury to the endothelial lining of the carotid artery in rats and 
then reappeared weeks later after the inner endothelial lining had re-formed [149].  
A few studies have shown density dependent effects of SPRY2 in fibroblasts and 
breast carcinoma cells [157, 171, 172]. However, a direct density-dependent regula-
tion of SPRY2 has not been described. Confluent p38α knock out MEFs showed in-
creased SPRY2 levels when compared to confluent wt MEFs. The authors suggested 
that p38α mediates growth arrest at confluence via SIAH2 dependent SPRY2 down-
regulation [172]. We therefore asked whether cell density dependent regulation of 
SPRY2 is restricted to endothelial cells. However, HBL-100 and Caco2 cells also ex-
hibit a cell density dependent regulation pattern of SPRY2 protein expression. Alt-
hough both cell lines grow to higher densities than endothelial cells, they exhibit a 
monolayer like structure and partial contact inhibition (Fig. 17). Therefore, it would be 
interesting to assess, whether Spry2 knockout in these cells would promote cancer 
growth and metastatic potential due to loss of monolayer integrity. Indeed, Sprouty 
protein expression is distinctly controlled in a number of cancers. In breast cancer 
cells, SPRY2 transcription is suppressed by aberrant hypermethylation [173]. McKie 
et al. have shown SPRY2 downregulation in prostate cancer [174], while others have 
reported SPRY2 downregulation in liver cancer [131].  
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7.2 Increased SPRY2 expression at high cell densities – Hypoxia, cell-cell 
contacts or both? 
Several mechanisms may increase SPRY2 protein at high cell density. SPRY2 pro-
tein levels steadily increased in endothelial cells growing towards confluency. In the 
sub-confluent phase, SPRY2 expression correlated with reduced oxygen saturation 
and increased HIF-1α protein levels. Exogenously applied hypoxia increased SPRY2 
protein in both sparse (results not shown) and confluent cells (Fig. 15). Together with 
data from a previous study demonstrating that hypoxia regulates Sprouty proteins by 
prolyl hydroxylases [145], these results point to hypoxia as a general post-
transcriptional stimulus for SPRY2. In vivo, hypoxia-induced SPRY2 expression may 
provide a protective homeostatic function when the vasculature is exposed to hypox-
ia. Endothelium that is subjected to oxygen deprivation maintains cell viability and 
basic biosynthetic mechanisms, but it displays multiple changes in barrier function, 
that are relevant to vascular homeostasis [175, 176].  
The observation that SPRY2 expression still remains elevated in confluent cells 
showing normoxic oxygen levels points to another essential mechanism for stabilizing 
SPRY2 in confluent cultures. We have ruled out the possibility that confluent cells 
secrete a soluble factor to stimulate SPRY2 expression, instead intact cell-cell con-
tact seem important. Indeed, targeting endothelial cell-cell contacts by Thrombin and 
TNFα [160, 161] decreased SPRY2 expression in confluent cells (Fig. 19). Accord-
ingly, TNFα downregulated SPRY2 in murine Swiss 3T3 fibroblasts and MLE15 lung 
epithelial cells. The authors speculated that TNFα modulated SPRY2 translation via 
p38 MAPK signaling [144]. Therefore, we cannot rule out that TNFα affected SPRY2 
protein by signaling events, which might be independent of cell-cell contacts. 
N- and VE-cadherins are components of endothelial adherens junctions [56, 163] and 
interact with cadherins of neighboring cells in a homophilic manner [57]. These adhe-
sive complexes strictly depend on extracellular calcium [59, 162]. We show that Ca2+ 
depletion disrupts cell-cell contacts and rapidly destabilizes SPRY2 protein. Con-
versely, re-establishing cell-cell contacts stabilizes SPRY2 protein again (Fig. 20). 
SPRY2 protein levels restores after recalcification at a stage, at which impermeability 
has not yet completely reestablished. Thus, singular cell-cell contacts are already 
sufficient to stabilize SPRY2 protein levels. Cadherin clustering-induced signaling 
events might stabilize SPRY2 levels when cells first touch each other before absolute 
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confluency is reached and junctions are fully stabilized [177, 178]. Interestingly, the 
addition of a VE-cadherin binding antibody increases SPRY2 protein levels in conflu-
ent but not in sparse cells (Fig. 21A). This antibody is supposed to block VE-cadherin 
homophilic interactions [164] but it might be possible that the antibody crosslinks ad-
jacent VE-cadherin and thereby induces cadherin signaling events [47, 54]. It might 
therefore be necessary to increases the blocking antibody concentration to interfere 
with the homophilic VE-cadherin interactions. Furthermore, it will be indispensable to 
use a corresponding control antibody. Indeed, when cells were plated in the pres-
ence of high concentrations of the VE-cadherin blocking antibody, the SPRY2 protein 
decreased (preliminary finding; results not shown). When we add soluble recombi-
nant VE-cadherin the opposite, i.e., inhibition of VE-cadherin clustering, may occur. 
Hereby, the soluble protein might interfere with existing VE-cadherin cell-contacts. 
However, the SPRY2 downregulation is also observed in sparse cells (Fig. 21B). 
Taken together, it remains uncertain how VE-cadherin influences SPRY2 expression.  
Taddei et al. described reduced Spry2 mRNA levels in confluent VE-cadherin ex-
pressing endothelial cells via inactivation and nuclear exclusion of the Spry2 tran-
scription factor FoxO1 [179]. This observation is in disagreement with our finding that 
FoxO1 phosphorylation decreases with higher cell-density (Fig. 18). Dephosphory-
lated FoxO1 exhibits increased transcriptional activity and predominantly localizes to 
the nucleus [159, 180]. Surprisingly, its downregulation by siRNA affects neither 
Spry2 transcription nor SPRY2 protein expression at high cell density (Fig. 18).  
Paik et al. have recently shown that FoxO silencing downregulated Spry2 in liver but 
not in lung endothelial cells [148]. An explanation for this observation could be a vas-
cular-bed-specific transcriptional regulation of Spry2 involving a specific set of tran-
scriptional co-activators. Beside the FoxO binding elements, the Spry2 promoter con-
tains at least on additional binding element for the ETS-1 transcription factor. Like the 
FoxOs, the ETS transcription factors are required for proper angiogenesis and endo-
thelial function [181]. However, whether ETS-1 effectively increases Spry2 expres-
sion is not known.  
In summary, two independent and consecutive stimuli – transient intrinsic hypoxia 
and establishment of cell-cell contacts – induce and stabilize SPRY2 protein levels. 
However the specific cell-cell contact molecule, which stabilizes SPRY2 at high cell 
densities, remains to be identified. 
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7.3  Hypoxia in cell cultures – a neglected factor? 
Although this study is not the first to show that oxygen saturation in conventional 
monolayer cell cultures may be considerably lower than in the incubation gas [158], 
this important fact remains ignored regularly. The emerging pericellular hypoxia likely 
affects cellular metabolism [182, 183], transcription [184], protein synthesis [185] and 
viability [186] and thus should be considered for the interpretation of in vitro results.  
When oxygen concentrations drop below their physiological levels, the cellular ener-
gy production is rapidly switched to anaerobic glycolysis [184], and the cell cycle of 
most cells is arrested to decrease the O2 demand [187]. Some specialized cells, i.e. 
vascular endothelial cells (ECs), vascular smooth muscle cells and embryonic fibro-
blasts increase their proliferation in response to hypoxia [41, 188] and participate in 
the formation of new microvessels to increase oxygen concentrations in particular 
tissues [189]. In vivo, the physiologic oxygen concentration in different tissues varies 
from 10-14% in arterial blood, to less than 10% in the myocardium, and to 8-2% in 
the liver, cartilage or bone marrow [167]. New technics such as real-time measure-
ment of the in-culture-oxygen saturation (Figs. 14, 15) allow monitoring the O2 con-
sumption of the cultured cells. This parameter then could be used to adapt the oxy-
gen saturation of cultured cells to the physiological oxygen concentration found in the 
corresponding tissue or organ thereby helping to better simulate the actual in vivo 
situation.  
 
7.4 SPRY2 expression controls monolayer integrity and quiescence via inhib-
iting FGF2-ERK1/2 signaling 
Mechanisms that restore, stabilize, and continue to maintain the endothelial barrier 
function are the final stage in the morphogenesis of new microvessel formation [3]. 
The inhibition of cell-cell contact promotes the switch from an angiogenic and prolif-
erative state to a quiescent endothelial cell phenotype. Membrane proteins, in addi-
tion to maintaining cell-cell adhesion, also sense cell-cell interactions and transduce 
this information to intracellular signals [2, 79]. Decoupling of the MAPK pathway is 
part of the mechanism that arrests growth in confluent endothelial cells [5].  
The findings of Vinals and Pouyssegur [5] and the results of this study (Fig. 22A1, 
A2) demonstrate that FGF2-induced MAPK activity decreased with time in confluent 
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cells. SPRY2 is a well-known feed-back loop inhibitor of RTK signaling and modu-
lates ERK1/2 activity in different settings [9]. Therefore, we hypothesize that SPRY2 
plays a role as a general feedback inhibitor of cell growth that might directly promote 
cessation of cell growth in the presence of cell-cell contacts.  
In confluent cells, SPRY2 expression correlated with decreased ERK1/2 activity (Fig. 
22C). Conversely, Spry2 knockout increased FGF2-induced ERK1/2 signaling in con-
fluent cell cultures (Fig. 24B). The finding that SPRY2 function is affected by cell 
density is in agreement with previous studies. Kajita et al. have shown that overex-
pression of SPRY2 inhibited PDGF-induced ERK1/2 activity in dense, but not in 
sparse NIH 3T3 fibroblast cell cultures [171]. In a similar fashion, SPRY2 function in 
T47D breast carcinoma cells also depended on cell density [157].  
ERK-dependent SPRY2 expression has been reported in many studies [10, 117, 
128, 134, 190, 191]. However, it is not known whether this expression pattern de-
pends on cell density. Based on the observation that FGF2 increases SPRY2 ex-
pression predominantly in confluent cells (Figs. 22B, C), we assume that FGF2-
induced SPRY2 expression might be somehow connected to cell-cell contacts and 
thereby allow cell-density dependent function of SPRY2. Indeed, preliminary results 
revealed that increasing cell density possibly dephosphorylates SPRY2 (results not 
shown). Lao et al. showed that SPRY2 dephosphorylation is a perquisite for ERK 
inhibition under certain circumstances [130]. At this point however, it is too soon to 
speculate whether this modification affects SPRY2 function at high cell density.  
Although FGF signaling has been identified as a strong pro-angiogenic factor in 
physiological [84] and pathological situations [192], Murakami et al. [83] have 
demonstrated that it also plays a key role in the maintenance of vascular integrity, 
because a loss of FGF results in severe impairment of the endothelial barrier function 
and eventually to a disintegration of the vasculature. Thus, it would not be favorable 
for endothelial cells to just block FGF signaling at confluence. Therefore, we propose 
that SPRY2, as key element embedded in the FGF system, might switch the re-
sponse of endothelial cells from proliferation and migration to survival and quies-
cence through control of ERK1/2 activity (Fig. 29).  
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Figure 29. A working model for the regulation of SPRY2-dependent endothelial quiescence and 
integrity. In wt endothelial cells (Spry2fl/fl), SPRY2 is upregulated by increasing cell density via transi-
ent hypoxia in subconfluent cells and cell-cell contacts in confluent cells. SPRY2 expression allows the 
endothelial monolayer to retain its integrity and cell quiescence, upon FGF stimulation. In the absence 
of SPRY2 (Spry2 knockout), FGF signaling extensively activates ERK1/2. ERK1/2 elicits an endotheli-
al phenotype change from cobble-stone to spindle shape endothelial cells, induces proliferation, and 
increases permeability. 
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Indeed, we show that SPRY2 regulates quiescence and integrity of the endothelial 
monolayer: Whereas the endothelial monolayer remains quiescent in wild type cells, 
with low mitogenicity, low basal permeability, and the typical cobblestone morpholo-
gy, the Spry2-/- cells fail to form a connected monolayer and exhibit a spindle-shaped 
morphology with increased proliferation and permeability. The observed phenotype is 
likely due to deregulated FGF signaling: First, ERK1/2 activity increases considerably 
in Spry2-/- cells during the early phase of monolayer formation and second, pre-
incubation of Spry2-/- cells with the MAPK inhibitor U0126 is sufficient to restore the 
wild type-like cobblestone phenotype. 
Experimental evidence in several studies suggests that FGF2 activates the 
VEGF/VEGFR system [193, 194]. Whereas fine-tuned intracellular VEGF-A/VEGFR-
2 signaling supports endothelial survival in established mature blood vessels [195], 
uncontrolled expression of VEGF-A exceeding physiological thresholds leads to the 
formation of unstable and leaky blood vessels [196] or even hemangiomas [197]. 
SPRY2 could potentially interfere with this signaling cascade and prevent activation 
of the VEGF/VEGFR system by FGF in quiescent blood vessels. Sasaki et al. 
showed that Sprouty4 suppressed VEGF induced ERK activation [142]. Therefore 
SPRY2 might also interfere with VEGF signaling in a similar fashion. 
Spry2 knockout animals display discrete developmental defects that have been at-
tributed to unrestricted FGF signaling [151, 153-155]. Although we observe that 
Spry2 knockout markedly affects endothelial quiescence and integrity in vitro, the 
Spry2 knockouts described so far exhibit rather mild malformations without an overt 
vascular phenotype. This discrepancy might be due to redundancies amongst the 
Sprouty isoforms in in vivo models. Furthermore, exposition of the knock out animals 
to stress such as severe hypoxia or to high doses of growth factors may hypothetical-
ly reveal additional SPRY2 specific phenotypes. 
Taken together, cell density (and FGF2)-induced SPRY2 may play a central role in 
terminating FGF-ERK1/2 signaling and thereby maintaining endothelial monolayer 
integrity and quiescence.  
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7.5 SPRY2 expression might be beneficial to treat disease related to dysregu-
lated FGF signaling in the vasculature  
The data of the present thesis revealed that high SPRY2 expression levels play a 
critical role in establishing endothelial monolayer integrity by inhibiting FGF2-induced 
ERK1/2 signaling. This negative feed-back loop may be important in situations, 
where endothelial monolayers form, where the regulation of basal permeability must 
be strict, and where vascular integrity and quiescence must be established and main-
tained in vivo.  
Although necessary to promote tissue repair, FGF2 may also worsen injuries [198] by 
contributing to the harmful neovascularization of chronic inflammatory diseases such 
as rheumatoid arthritis [199] and inflammatory bowel disease [200]. SPRY2 expres-
sion at sites of chronic inflammation might therefore locally restrict these negative 
effects of FGF secretion.  
Despite having an abundant number of vessels, tumors are usually hypoxic and nu-
trient-deprived because their disturbed vessel architecture [169]. Such abnormal mi-
lieu impairs drug delivery and enhances the metastatic potential. Preclinical and initial 
clinical studies revealed that tumor vessel normalization is a promising complemen-
tary therapeutic approach to treat cancer [20, 201]. We propose that SPRY2 expres-
sion may be an option to sequester excessive FGF-signaling and to redirect it from 
vessel growth to the maintenance of vascular integrity thereby contributing to tumor 
vessel normalization. 
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8 CONCLUSION AND KEY POINTS 
In conclusion, the data of the present thesis show for the first time that high SPRY2 
expression levels play a critical role in endothelial monolayer establishment and 
maintenance. In wild type MAECs, SPRY2 expression was driven by transient hypox-
ia and emerging cell-cell contacts in cells growing to high density, whereas expres-
sion was reduced in sparse single proliferating cells. We were particularly interested 
to determine how endothelial cells process signals arising from increasing cell density 
to allow a switch from a proliferative, migratory phenotype to a quiescent, impermea-
ble monolayer. We therefore compared the ability of primary Spry2 expressing 
(Spry2fl/fl) and Spry2 knockout (Spry2-/-) mouse aortic endothelial cells (MAECs) to 
form a functional endothelial monolayer. Spry2 knockout MAECs were incapable of 
forming a functional, impermeable endothelial monolayer in the presence of FGF2 
when grown to high cell densities. Dense Spry2 knockout MAECs showed spindle-
like shapes, unrestricted proliferation, and exhibited enhanced signaling by the FGF2 
downstream target ERK1/2. Wild type cobblestone monolayer morphology, however, 
was restored upon inhibiting ERK1/2 activity in Spry2 knockout cells. The main find-
ings can be summarized in the following key points: 
 
1. SPRY2 expression increases with higher cell densities in mouse aortic endo-
thelial cells.  
2. Transient hypoxia increase SPRY2 protein expression during the formation of 
the endothelial monolayer. 
3. Calcium dependent cell-cell contacts stabilize SPRY2 protein at confluence. 
4. At high cell-densities, enhanced SPRY2 protein levels correlate with de-
creased ERK1/2 phosphorylation. 
5. Dense Spry2-/- cells exhibit increased FGF2-induced ERK1/2 signaling. 
6. In the presence of FGF2, dense Spry2 knockout cells loose contact inhibition 
and the ability of forming a functional, impermeable monolayer. 
7. Inhibition of ERK1/2 in Spry2 knockout MAECs restores the wild type cobble-
stone monolayer morphology. 
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9 LIMITATIONS AND OUTLOOK 
The following limitations may restrict the significance of the present study: most of the 
experiments in this study were performed with MAECs. It is difficult to predict whether 
the effects of the studied molecules are conserved in other species, e.g. humans. It is 
unclear whether our data can be extrapolated to other vascular cell types and tis-
sues. Besides, the readouts of the in vitro studies performed may not reflect the in 
vivo situation. Therefore, caution should be taken when the data are utilized to inter-
pret in vivo or clinical phenomena. 
 
Additional studies are required to solve many unanswered questions. First, it would 
be interesting to identify the decisive cell-cell contact molecule(s) which is (are) in-
volved in SPRY2 stabilization at high cell-densities. Future studies might focus on the 
adherens junction molecule VE-cadherin. Although some results point to an involve-
ment of VE-cadherin in SPRY2 regulation, we were unable to prove the direct con-
nection. The investigation of SPRY2 expression in VE-cadherin knockout endothelial 
cells would be informative. 
Furthermore, potential downstream targets of FGF-induced ERK1/2 signaling need to 
be investigated to better understand the observed Spry2 knockout phenotype. It 
would also be interesting to see whether the expression of the other SPRY isoforms 
(SPRY1, 3 and 4) is affected by Spry2 knockout and whether a co-silencing of 
SPRY1, 3, or 4 would intensify the observed Spry2 knockout phenotype in MAECs.  
Finally, we would like to propose that decreased SPRY2 expression might serve as a 
prognostic marker for altered vascular permeability and thus, for an increased sus-
ceptibility for disease related to defects in the endothelial barrier. 
Although the in vivo relevance of our findings remains to be confirmed, our results 
add to the understanding of how endothelial cells control cell density to switch from a 
proliferative, migratory phenotype to a quiescent, impermeable monolayer – a pro-
cess which is crucial not only in the formation of stable and functional blood vessels, 
but also during organogenesis in general [2, 79, 80].  
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11 ABBREVIATIONS 
AJ  = Adherens Junction 
ANG2  = Angiotensin 2 
BBB  = Blood Brain Barrier 
C  = Confluent 
CBL  = Casitas B-lineage Lymphoma proto-oncogene product 
CO2  = Carbon Dioxide 
CRD  = Cysteine-Rich Domain 
DAG  = Diacylglycerol 
DLL4  = Delta like ligand 4 
DMEM  = Dulbecco's Minimal Essential Medium 
DSPRY  = Drosophila Sprouty 
EC  = Endothelial Cell 
EGF   = Epidermal Growth Factor 
EGFR  = Epidermal Growth Factor Receptor 
EGTA  = Ethylene Glycol Tetraacetic Acid 
EMT  = Epithelial-to-Mesenchymal Transition  
eNOS  = Endothelial Nitric Oxide Synthase 
ERK1/2  = Extracellular signal-Regulated Kinase 1/2 
ESAM  = Endothelial cell Selective Adhesion Molecule 
FCS   = Fetal Calf Serum 
FGF   = Fibroblast Growth Factor 
FGFR  = Fibroblast Growth Factor Receptor 
GDNF  = Glial-Derived Growth Factor 
GRB2  = Growth factor Receptor-Bound protein 2 
HACE  = High Altitude Cerebral Edema  
HIF-1α  = Hypoxia inducible Factor alpha 
HMVEC = Human Microvascular Endothelial Cell  
HRE   = Hypoxia Response Element 
HT   = Human Thrombin 
HUVEC = Human Umbilical Endothelial Cell 
IL-1  = Interleukin-1 
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IP3  = Inositol (1,4,5)-Trisphosphate 
JAM-A = Junctional Adhesion Molecule A 
KO   = knockout 
LDL   = Low-Density Lipoprotein  
MAEC = Mouse Aortic Endothelial Cell 
MAPK  = Mitogen-Activated Protein Kinase 
MEK  = MAPK and ERK kinase 
MLC  = Myosin light chain 
MLCK  = Myosin light chain kinase 
MMP  = Matrix Metalloproteinases 
NO   = Nitric Oxide 
NOS   = Nitric Oxide Synthase 
O2  = Oxygen 
PC  = Pericyte 
PDGF  = Platelet-Derived Growth Factor 
PHD  = Prolyl Hydroxylase Domain-containing protein 
PIGF   = Placental Growth Factor  
PIP2  = Phosphatidylinositol (4,5)-Bisphosphate  
PI3K   = Phosphatidylinositol-3-kinase 
PKA  = Protein Kinase A 
PKC  = Protein Kinase C 
PLCγ   = Phospholipase C gamma 
PP2A  = Protein Phosphatase 2A 
PVC  = Perivascular Cell 
p44/p42  = ERK1/2 
RBD  = Raf1-Binding Domain  
RHOA = Rho kinase A  
ROCK = RhoA kinase 
RTK   = Receptor Tyrosine Kinase  
SC  = Sub Confluent 
Ser  = Serine 
SHP2  = SH2-domain containing protein tyrosine Phosphatase 2 
SIAH2 = Seven-In-Absentia Homolog 2 
SOS1  = Son of Sevenless 1  
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SP  = Sparse 
SPRY2  = Sprouty2 
TGFβ   = Tumor Growth Factor beta 
Thr  = Threonine 
TJ  = Tight Junction 
TNFα   = Tumor Necrosis Factor alpha 
VEGF  = Vascular Endothelial Growth Factor 
VEGFR = Vascular Endothelial Growth Factor Receptor 
VHL  = von Hippel-Lindau protein 
VSMC  = vascular smooth muscle cell 
(Y)  = Tyrosine  
ZO-1   = Zonula Occludens 1 (Tight junction protein 1) 
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